Plasma Metabolomic and Lipidomic Alterations Associated with COVID-19

Di Wu[1,2,#], Ting Shu[3,4,2,#], Xiaobo Yang[5,#], Jian-Xin Song[6,#], Mingliang Zhang[7,#], Chengye Yao[8,#], Wen Liu[3,4], Muhan Huang[1,2], Yuan Yu[5], Qingyu Yang[3,4,2], Tingju Zhu[3,4], Jiqian Xu[5], Jingfang Mu[1,2], Yaxin Wang[5], Hong Wang[7], Tang Tang[7], Yujie Ren[1,2], Yongran Wu[5], Shu-Hai Lin[9]*, Yang Qiu[1,2,3,10]*, Ding-Yu Zhang[3,4]*, You Shang[5,3,4]*, Xi Zhou[1,2,3,10]*

[1] Joint Laboratory of Infectious Diseases and Health, Wuhan Institute of Virology & Wuhan Jinyintan Hospital, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences (CAS), Wuhan, Hubei 430023 China

[2] State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, CAS, Wuhan, Hubei 430071, China

[3] Center for Translational Medicine, Jinyintan Hospital, Wuhan, Hubei 430023 China

[4] Joint Laboratory of Infectious Diseases and Health, Wuhan Institute of Virology & Wuhan Jinyintan Hospital, Wuhan Jinyintan Hospital, Wuhan, Hubei 430023 China

[5] Department of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030 China

[6] Department of Infectious Diseases, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030 China

[7] Wuhan Metware Biotechnology Co., Ltd, Wuhan, Hubei 430075 China

[8] Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022 China

[9] State Key Laboratory of Cellular Stress Biology, Innovation Center for Cell Signaling Network, School of Life Sciences, Xiamen University, Xiamen, Fujian 361102 China

[10] University of Chinese Academy of Sciences, Beijing 100049 China

[#] These authors contributed equally

*Correspondence: zhouxi@wh.iov.cn (X.Z.), you_shanghust@163.com (Y.S.), zhangdy@hotmail.com (D.-Y.Z.), yangqiu@wh.iov.cn (Y.Q.), shuhai@xmu.edu.cn (S-H.L)

Abstract

The pandemic of the coronavirus disease 2019 (COVID-19) has become a global public health crisis. The symptoms of COVID-19 range from mild to severe conditions. However, the physiological changes associated with COVID-19 are barely understood. In this study, we performed targeted metabolomic and lipidomic analyses of plasma from a cohort of COVID-19 patients who had experienced different symptoms. We found the metabolite and lipid alterations exhibit apparent correlation with the course of disease in these COVID-19 patients, indicating that the development of COVID-19 affected whole-body metabolism of the patients. In particular, malic acid of the TCA cycle and carbamoyl phosphate of urea cycle reveal the altered energy metabolism and hepatic dysfunction, respectively. It should be noted that carbamoyl phosphate is profoundly down-regulated in fatal patients compared with mild patients. And more importantly, guanosine monophosphate (GMP), which is mediated by not only GMP synthase but also CD39 and CD73, is significant changed between healthy subjects and COVID-19 patients, as well as between the mild and fatal groups. In addition, the dyslipidaemia was observed in COVID-19 patients. Overall, the disturbed metabolic patterns have been found to align with the progress and severity of COVID-19. This work provides valuable knowledge about plasma biomarkers associated with COVID-19 and potential therapeutic targets, as well as important resource for further studies of COVID-19 pathogenesis.

Introduction

The outbreak of COVID-19, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been declared a pandemic by the World Health Organization (WHO). Up to the date of April 13, 2020, there are over 1.8 million confirmed COVID-19 cases and more than 110,000 deaths worldwide according to the situation report of WHO. Based on a recent study of 44,672 confirmed COVID-19 cases up to February 11 by Chinese Center for Disease Control and Prevention, over 19% COVID-19 patients developed severe or critical conditions (1). The global fatality rate is around 4.8% in all the confirmed cases until March 31, and has even reached 10% in some developed countries probably due to a more elderly population (2).

The main attacking organ of SARS-CoV-2 is low respiratory tract, and some patients develop life-threatening acute respiratory distress syndrome (ARDS). Besides, the attacks of liver, muscle, gastrointestinal tract, lymph node, and heart by SARS-CoV-2 have also been found or proposed (3-6). On the other hand, although more than 80% COVID-19 patients experienced only mild symptoms, it has been found that the conditions can rapidly progress from mild to severe ones, particularly in the absence of adequate medical care. Moreover, the mortality rate of COVID-19 in critically ill cases can be over 60%, posing great pressure on treatment (7). However, the physiological changes associated with COVID-19 under different symptomatic conditions are barely understood.

Metabolites and lipids are major molecular constituents in human plasma. During critical illness, metabolic and lipid abnormalities are commonly observed, which are

believed to contribute to physiology and pathology. Moreover, previous studies have demonstrated dramatic alterations of metabolome and lipidome in human plasma caused by various diseases including viral infections, like Ebola virus disease (8, 9). Here, we performed the targeted metabolomic and lipidomic profilings of plasma samples collected from a cohort of COVID-19 patients, including COVID-19 fatalities and survivors recovered from mild or severe symptoms. Our findings here show many of the metabolite and lipid alterations, particularly ones associated with hepatic functions, align with the progress and severity of the disease, which would provide valuable knowledge about plasma biomarkers associated with COVID-19 as well as potential therapeutic targets, and shed light on the pathogenesis of COVID-19.

Results

Study design and patients

Blood samples were harvested at Wuhan Jinyintan Hospital from COVID-19 patients who were confirmed by laboratory nucleic acid test of SARS-CoV-2 infection. Serial samples were collected over the course of disease from 9 patients with fatal (F) outcome (F1-F4), 11 patients diagnosed as severe (S) symptoms (S1-S2), and 14 patients diagnosed as mild (M) symptoms (M1-M2) (Table S1). Of note, all the patients in the severe (S) and mild (M) groups had survived from COVID-19 and been discharged from the hospital. F1 represents the first samples collected from the COVID-19 fatal patients, while F4 represents the last samples before additional samples could be collected. S1 or M1 represents the samples during the disease peak of the patients in the severe or mild group as being determined based on the Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (6th edition) published by the National Health Commission of China (10), while S2 or M2 represents the last samples collected from patients in each group before the patients discharged from the hospital. For comparison, the blood samples from 10 healthy volunteers, whose throat swabs and serological testing were negative for SARS-CoV-2, were collected. The hydrophilic and hydrophobic metabolites were extracted from each plasma sample, respectively and measured by employing liquid chromatography electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS) system. The metabolite identification was conducted by home-made database with retention time and ion pairs. For those metabolites without authentic standards in our database, we still used MS/MS spectra to search against the

public databases for improving the confidence of metabolite identification. The orthogonal partial least-squares discriminant analysis (OPLS-DA) was used to discriminate metabolomics profiles between the groups of COVID-19 patients and healthy people (Figure S1-S4). In total, 431 metabolites and 698 lipids were identified and quantified, and both metabolome and lipidome showed dramatic alterations in the plasma of these COVID-19 patients (Table S2 and S3).

Plasma metabolomic alternations associated with clinical symptoms of COVID-19

For different courses of fatal COVID-19 patients (F1-F4), we analyzed the metabolites that underwent significant change [F4 vs. H, >1 $\log_2$ fold change (FC) <-1, typically P <0.05]. For F vs. H, 87 of the total 431 metabolites were significantly different ($P < 0.05$) at F1, while the number of significantly altered metabolites were increased to 162 at F4 in the fatalities; and most of the changes are down-regulated (Table S2). We found a positive correlation between the alteration of metabolites and the course of disease deterioration in fatal patients (Figure 1A and Table S4), indicating that the development of disease affects the metabolism of metabolites.

We also profiled the metabolites in the different courses of severe and mild COVID-19 patients (S1 and S2; M1 and M2), and analyzed those that underwent the significant change [S1 vs. H, >1 $\log_2$ FC <-1, typically P <0.05; M1 vs. H, >1 $\log_2$ FC <-1, typically P <0.05] (Figure 1B and Table S5). There are apparently less metabolites with significant changes (>1 $\log_2$ FC <-1, typically P <0.05) observed in severe and mild patient groups when compared with those of fatal patients, and almost all the

significantly altered metabolites were down-regulated. These results indicate that the alterations of metabolic pathways were more dramatic in fatal COVID-19 cases than in severe and mild ones who finally survived.

In addition, it is noteworthy that although the patients in both severe and mild groups had met the hospital discharge criteria in the time points S2 and M2 as their COVID-19 nucleic acid tests for turning out to be negative twice consecutively, our metabolomic data clearly show that many of their metabolites had not returned to normal levels when compared with those in healthy volunteers (Figure 1B), suggesting that these discharged patients had not been fully recovered from the impacts of COVID-19 in physiology.

To further analyze the metabolomic data, the differentiating metabolites were divided into those shared by all groups (F vs. H, S vs. H, and M vs. H) or those unique to the fatal group (F vs. H). Then, we performed Kyoto Encyclopedia of Genes and Genomes (KEGG) functional enrichment analysis to annotate the potential functional implication of differentiating metabolites among these groups (Figure 2). As shared by all the three symptomatic groups, differentiating metabolites were enriched in total 12 pathways and significantly enriched in 3 pathways including pyrimidine metabolism, fructose and mannose metabolism, and carbon metabolism (Figure 2A-B and Table S6).

On the other hand, in the case of the fatality group, differentiating metabolites were significantly enriched in 4 pathways, including thyroid hormone synthesis, thyroid hormone signaling, purine metabolism, and autoimmune thyroid (Figure 2C-D and Table S7), suggesting that the alterations in these pathways are associated with the

progress and deterioration of COVID-19.

A prominent signature observed among fatal COVID-19 patients was an acute reduction of metabolites in patient plasma with the aggravation of the course of COVID-19. By comparing healthy subjects and fatal patients, we highlighted top 5 differentiating metabolites (Figure 3). For instance, malic acid, an intermediate of the tricarboxylic acid (TCA) cycle, exhibited the greatest log_2 FC (-5.2) among all significantly altered metabolites in the fatalities. Similarly, aspartic acid shows markedly down-regulated in the plasma of patients (Table S4 and Table S5). Thereby, we postulate that a deficiency of malic acid as well as dysfunction of malate-aspartate shuttle may reveal energy depletion and physical exhaustion in COVID-19 patients. These biomarkers are rapidly consumed in inflammatory states to provide energy and materials for the proliferation and phagocytosis of immune cells (11), indicating that immune system were activated in these cases.

Intriguingly, we observed that the levels of some nucleotides and organic acids were significantly increased (e.g., hypoxanthine), whereas the levels of some nucleotides and organic acids were significantly reduced [e.g., guanosine monophosphate (GMP)]. Hypoxanthine-guanine phosphoribosyl transferase (HPRT) is an important enzyme involved in nucleotide recycle pathway and can covert hypoxanthine and guanine to inosine 5'-monophosphate (IMP) and GMP, respectively (12, 13). The observed abnormal levels of hypoxanthine and GMP suggested that the function of HPRT had become defective in these COVID-19 fatal patients, which could result in the disorders of purine and pyrimidine metabolism. Furthermore, GMP is also

involved the metabolic reactions mediated by not only GMP synthase but also CD39 and CD73. Both CD39 and CD73 are the immunomodulatory enzymes, suggesting that CD39/CD73 axis imbalance may occur in COVID-19 patients. In addition, we observed that the level of carbamoyl phosphate was significantly and gradually reduced over the course of COVID-19 fatalities. Carbamoyl phosphate is synthesized from free amino donors by carbamoyl phosphate synthetase I (CPSI) in mitochondria of liver cells, and participates in the urea cycle to remove excess ammonia and produce urea (14-17). Its reduction in fatal cases of COVID-19 suggests the possibility of liver damage, which could also impair amino acid and pyrimidine metabolisms since CPSI could also maintain pyrimidine pool. Notably, both GMP and carbamoyl phosphate show significant changes between fatal and mild patients, indicating that the disease progression is associated with immune dysfunction and nucleotide metabolism.

Plasma lipidomic alternations correspond to clinical symptoms of COVID-19

We analyzed the lipids in different courses of fatal COVID-19 patients (F1-F4) that underwent significant change [F4 vs. H, >1 $\log_2$ FC <-1, typically P <0.05]. Most of the significantly changed lipids are up-regulated and a positive correlation between the alteration of lipids and the course of disease deterioration could be readily observed in the fatal patients (Figure 4A and Table S8). Lipid subclasses including diglycerides (DGs), free fatty acids (FAAs), and triglycerides (TGs), were identified in higher abundance in the fatality group (F vs. H), and the relative abundances of these lipids increased with the deterioration of the disease. Particularly, DG(16:0/20:2/0:0)

exhibited the greatest $\log_2$ FC (+4.15) in DGs, and TG(14:0/22:1/22:3) exhibited the greatest $\log_2$ FC (+4.17) in all significantly altered TGs. The increases of DGs, FFAs, and TGs under pathological conditions have been previously reported. For instance, lipolysis of adipose tissue increases due to EBOV infection, which converts TG to FFA and DG, and also results in enhanced recycling of the fatty acids back into TGs (9).

Besides, we observed that phosphatidylcholines (PCs) were gradually reduced over the course of COVID-19 fatalities. PCs are synthesized in the liver and are the only phospholipid necessary for lipoprotein (18); therefore, the COVID-19-associated decrease of PCs in the fatality group indicates hepatic impairments happened in the fatality group. Additionally, decreases in lysophosphatidylcholines (LPCs) and PCs in blood plasma have been observed in sepsis, cancer, and Dengue infection (19-22).

We also analyzed the lipids in different courses of severe and mild COVID-19 patients (S1 and S2; M1 and M2) that underwent the significant change [S1 vs. H, >1 $\log_2$ FC <-1, typically P <0.05; M1 vs. H, >1 $\log_2$ FC <-1, typically P <0.05] (Figure 4B and Table S9). Similar to those of metabolites, the total numbers of significantly altered lipids (>1 $\log_2$ fold change (FC) <-1, typically P <0.05) in the severe and mild groups (S1 vs H, S2 vs H, M1 vs. H, and M2 vs H) were similar, which are significantly less than the number of altered lipids in the fatality group, indicating that the alterations of lipid metabolism were much more dramatic in fatal COVID-19 patients than in survivors. Besides, for either severe or mild groups of patients, many of their lipids had not returned to normal before their discharge from hospital (Figure 4B, S2 vs H and M2 vs H), even though SARS-CoV-2 could not be detected and the major clinical signs had

disappeared in these patients based on official discharge criteria. Obviously, like the observations of metabolomic alterations, these discharged patients, no matter if they had experienced severe or mild symptoms, had not been fully recovered from the aftermath of COVID-19 in the aspects of both metabolite and lipid metabolisms.

Furthermore, the differentiating lipids were divided into those shared by all groups (F vs. H and S vs. H plus M vs. H) or those unique to the fatality group (F vs. H), and subsequently subjected to KEGG functional enrichment analysis. As shared by all the three symptomatic groups, differentiating lipids were enriched in total 7 pathways and significantly enriched in 4 pathways, including phosphatidylinositol signaling system, long-term depression, leishmaniasis, and inositol phosphate metabolism (Figure 5A-B and Table S10). In the case of fatality group, differentiating lipids were significantly enriched in 6 pathways, including retrograde endocannabinoid signaling, pathogenic *Escherichia coli* infection, Kaposi sarcoma-associated herpesvirus infection, glycosylphosphatidylinositol-anchor biosynthesis, glycerophospholipid metabolism and autophagy (Figure 5C-D and Table S11).

To highlight the top differentiating lipids, we showed 8 down-regulated lipids and 7 up-regulated lipids in COVID-19 patients compared with those in the healthy group (Figure 6 and Table S12), suggesting the dyslipidaemia in COVID-19 patients.

Logistic regression and receiver operating characteristic curve analysis

To rule out the possibility of potential biomarkers induced by age difference and/or gender disparity, we developed a logistic regression model for COVID-19 patients and

healthy controls. As shown in Table 1, the *P*-value from either age or gender variable shows no statistically significant differences on metabolic alterations, even though patients were older with the progression of disease.

Next, we generated ROC curves to assess the potential usefulness of plasma metabolite signatures for the diagnosis of COVID-19. Our ROC analyses revealed that combined five plasma metabolites were robust in discriminating COVID-19 patients from controls, with an area under the curve (AUC) value of 1.00 (data not shown). Then we analyzed ROC curve of each metabolite between COVID-19 and healthy subjects, revealing that malic acid and D-Xylulose 5-phosphate (Xu-5-P) show the best AUC values of 0.994 and 0.959, respectively (Figure 7A). Furthermore, the combined five plasma metabolite panel discriminating fatal group from mild group (Figure 7B), discriminating severe group from mild group (Figure 7C), and fatal group from severe group (Figure 7D) in ROC analysis, show the AUC values of 0.865, 0.708, and 0.737, respectively. Therefore, the combined five plasma metabolites could be a useful panel for COVID-19 diagnosis. Moreover, we further generated ROC curves of down-regulated lipids (Figure 7E) and up-regulated lipids (Figure 7F) for discriminating COVID-19 patients and healthy controls, respectively. Intriguingly, ROC curve analysis of glycerol 3-phosphate with an AUC value of 1.00 was observed, suggesting that circulating glycerol 3-phosphate would be a good biomarker for COVID-19. These obtained results suggest metabolomics and lipidomics provide a potential tool for disease diagnosis and drug targets in the current pandemic.

Discussion

The main purposes of this study were to generate a high-quality resource of metabolomic and lipidomic datasets associated with COVID-19 and identify the potential biomarkers for disease diagnosis for a better understanding of the pathogenesis of COVID-19.

Among the highlighted biomarkers, malic acid and glycerol 3-phosphate showed the greatest reduction when comparing the fatality patients with healthy volunteers, and also showed dramatic reduction in both severe and mild groups. Malic acid has important physiological functions, as it can directly enter the circulation of TCA cycle to participate in human energy metabolism. Besides, malic acid can accelerate ammonia transformation to lower ammonia concentration in liver and to protect liver (23, 24). Therefore, the dramatic reduction of malic acid is consistent with the hepatic impairment associated with COVID-19. Moreover, malic acid has been found to protect endothelial cells of human blood vessels and resist damage to endothelial cells.

Xu-5-P is a metabolite of the pentose phosphate pathway that mediates the effects of carbohydrate feeding on the glycolytic pathway, as well as fatty acid and triglyceride synthesis. Xu-5-P is the coordinating signal that both activates phosphofructokinase in glycolysis and promotes transcription of the genes for lipogenesis, the hexose monophosphate shunt, and glycolysis, and is required for *de novo* synthesis of fat and hepatic energy utilization (25-28). The reduction of Xu-5-P indicates that altered glucose and lipid metabolisms are also a reflection of hepatic impairment.

Carbamoyl phosphate is an important intermediate metabolite involved in removing excess ammonia in the urea cycle (14, 15). This metabolite is the downstream product of CPSI in mitochondria of liver cells. The observed down-regulation of carbamoyl phosphate levels is associated with the severity of COVID-19, as its level in the mild patients were affected in the least extent. Importantly, the dramatic reduction of carbamoyl phosphate is usually associated with urea cycle disorder, raising the concern about the possibility of hyperammonemia and liver failure in COVID-19 patients. The postulation seems to be consistent with deficiency of malic acid as mentioned above. In addition, the metabolisms of purine and thyroid hormones were significantly altered in the fatality group. Purine metabolism mainly occurs in human liver, and the thyroid hormone can affect hepatic protein synthesis and glycogen decomposition. Therefore, our findings show that the development of COVID-19 can cause hepatic impairment in these patients, which is consistent with the observations that a large number of COVID-19 patients showed liver function abnormalities (Table S13) (6).

Besides, the reductions of dihydrouracil, an intermediate breakdown product of uracil and guanosine monophosphate (GMP) (29), are proposed to be caused by the defects of human metabolism. It should be noted that GMP production is not only mediated by GMP synthase but also CD39 and CD73. Indeed, CD39/CD73 axis plays a crucial role in immunity and inflammation (30). Another metabolite glycerol 3-phosphate is a conserved three-carbon sugar and an obligatory component of energy-producing reactions including glycolysis and glycerolipid biosynthesis (31). Moreover,

glycerol 3-phosphate is an important mobile regulator of systemic acquired resistance, which provides broad spectrum systemic immunity in response to pathogenic infections (32). These metabolites show good correlation with the progress and severity of COVID-19, and can therefore serve as biochemical indicators for immune dysfunction of this disease.

Meanwhile, the lipids involved in glycerol metabolism pathway were upregulated, which maintain the balance of the energy metabolites of the body and are beneficial to the energy required for viral replication, suggesting that SARS-CoV-2 probably hijacks cellular metabolism like many other viruses (33). Our data show that the metabolic pathway of glycerophospholipids has been significantly changed, and glycerophospholipids are closely related with cardiovascular diseases. However, we did not find obvious pattern or significant difference of underlying diseases, such as hypertension, cardiac disease, diabetes, cerebrovascular disease, chronic hepatitis, and cancer, in the medical records of all the patient groups involved in this study. Therefore, this finding suggests that the fatality caused by COVID-19 might be related with cardiac impairment. Interestingly, COVID-19 has been recently reported to probably cause the loss of the smell and taste sense (https://www.npr.org/sections/goatsandsoda/2020/03/26/821582951/is-loss-of-smell-and-taste-a-symptom-of-covid-19-doctors-want-to-find-out), and the KEGG analysis also showed that the taste transduction pathway is affected.

The metabolomic and lipidomic analyses also show that, although the patients in both the severe and mild symptom groups had met the official hospital discharge criteria

as their COVID-19 nucleic acid tests for turning out to be negative consecutively twice and major clinical signs disappeared, many of their fundamental metabolites and lipids failed to return to normal. This finding suggests that these discharged patients, regardless of the severity of their previous symptoms, had not been fully recovered from the disease in the aspect of metabolism, particularly hepatic functions. Therefore, even after the clearance of SARS-CoV-2 from patient bodies, these convalescent COVID-19 patients still need better nutrition and care that would be very helpful for their faster and full recovery from the disease.

The metabolomic and lipidomic alterations in patient plasma mainly reflect the systematic responses of the metabolisms of diverse cell types and organ systems that were affected by SARS-CoV-2. Therefore, the interpretations of the datasets should be integrated with other types of system studies, such as the transcriptome and proteome of specific tissue and body fluid samples, as well as clinical observations and laboratory examinations, to have a clearer and more comprehensive picture of the development of this disease. Moreover, such an integration would help us to better understand the impacts of COVID-19 to specific cells and/or tissues infected by SARS-CoV-2.

In summary, the metabolomic and lipidomic datasets of the cohort of COVID-19 patients under different symptomatic conditions are highly valuable resources for a better understanding of the host metabolic responses associated with COVID-19, which expands our knowledge about the pathogenesis of COVID-19, accelerates identification of disease biomarkers and development of diagnostic assays, and provides hints of potential therapeutic strategies.

Materials and Methods

Materials and methods are detailed described in Supplementary data.

Supplementary data

Supplementary methods and materials

Supplementary Figure S1-S4

Supplementary Table S1-S15

Author contributions

D.W., T.S., X.Y. and J.-X.S. performed experiments with the help of W.L., M.H., Y.Y., Q.Y., T.Z., J.X., Y.W., J.M., H.W., T.T., Y.R. Y.W.; M.Z., C.Y. and S.-H.L. analyzed the metabolomics and lipidomics data with the help of D.W. and Y.Q.; S.-H.L., Y.Q., D.-Y.Z., Y.S., and X.Z. performed the experimental design and data interpretation; X.Z, Y.Q., Y.S., D.-Y.Z. and S.-H.L. analyzed the data and wrote the paper; X.Z, Y.Q., Y.S. and D.-Y.Z. designed and supervised the overall study.

Competing Interests statement

The authors declare no conflicts of interest.

Acknowledgments

We thank the patients, and the nurses and clinical staffs who are providing care for these patients. We thank the helpful discussions with Drs. Yan Wang and Yong Liu at Wuhan University. We also thank many staff members at Wuhan Jinyintan Hospital and

Wuhan Metware Biotechnology Co., Ltd. for their contributions and assistance in this study. We sincerely pay tribute to our colleagues who have strived in the forefront of taking care of COVID-19 patients and are studying this novel coronavirus in Wuhan and other places around the world.

This work was supported by the Strategic Priority Research Program of CAS (XDB29010300 to X.Z.), the National Science and Technology Major Project (2020ZX09201-001 to D.-Y.Z, and 2018ZX10101004 to X.Z.), National Natural Science Foundation of China (81873964 to Y.Q., 31670161 to X.Z., 81971818, and 81772047 to Y.S.), the Fundamental Research Funds for the Central Universities (20720200013 to S-H.L.), and Grant from Clinical Research Center for Anesthesiology of Hubei Province (No.2019ACA167).

References

1.   The Novel Coronavirus Pneumonia Emergency Response Epidemiology, T. The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) — China, 2020. *China CDC Weekly*. 2020; **2**(8): 113-22.

2.   WHO. Coronavirus disease 2019 (COVID-19) Situation Report - 71. *https://wwwwhoint/docs/default-source/coronaviruse/situation-reports/20200331-sitrep-71-covid-19pdf?sfvrsn=4360e92b_4 (accessed March 31, 2020)*. 2020.

3.   Wang, D, Hu, B, Hu, C*, et al.* Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA*. 2020.

4.   Huang, C, Wang, Y, Li, X*, et al.* Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020.

5.   Chen, N, Zhou, M, Dong, X*, et al.* Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet*. 2020.

6.   Zhang, C, Shi, L, Wang, FS. Liver injury in COVID-19: management and challenges. *Lancet Gastroenterol Hepatol*. 2020.

7.   Yang, X, Yu, Y, Xu, J*, et al.* Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *The Lancet Respiratory Medicine*. 2020.

8.   Eisfeld, AJ, Halfmann, PJ, Wendler, JP*, et al.* Multi-platform 'Omics Analysis of Human Ebola Virus Disease Pathogenesis. *Cell Host Microbe*. 2017; **22**(6): 817-29 e8.

9.   Kyle, JE, Burnum-Johnson, KE, Wendler, JP*, et al.* Plasma lipidome reveals critical illness and recovery from human Ebola virus disease. *Proc Natl Acad Sci U S A*. 2019; **116**(9): 3919-28.

10.   National Health Commission of China, T. National Health Commission of China. *New coronavirus pneumonia prevention and control program (6th edn) http://wwwnhcgovcn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8aefc2/files/b218cfeb1bc54 639af227f922bf6b817pdf (accessed Feb 18, 2020; in Chinese)*. 2020.

11.   Soeters, PB, Grecu, I. Have we enough glutamine and how does it work? A clinician's view. *Ann Nutr Metab*. 2012; **60**(1): 17-26.

12.   Lopez-Cruz, RI, Crocker, DE, Gaxiola-Robles, R*, et al.* Plasma Hypoxanthine-Guanine Phosphoribosyl Transferase Activity in Bottlenose Dolphins Contributes to Avoiding Accumulation of Non-recyclable Purines. *Front Physiol*. 2016; **7**: 213.

13.   Auler, K, Broock, R, Nyhan, WL. Determination of Activity of the Enzymes Hypoxanthine Phosphoribosyl Transferase (HPRT) and Adenine Phosphoribosyl Transferase (APRT) in Blood Spots on Filter Paper. *Curr Protoc Hum Genet*. 2015; **86**: 17 9 1- 9 0.

14.   Sigoillot, FD, Kotsis, DH, Serre, V*, et al.* Nuclear localization and mitogen-activated protein kinase phosphorylation of the multifunctional protein CAD. *J Biol Chem*. 2005; **280**(27): 25611-20.

15.   Struck, J, Uhlein, M, Morgenthaler, NG*, et al.* Release of the mitochondrial enzyme carbamoyl phosphate synthase under septic conditions. *Shock*. 2005; **23**(6): 533-8.

16.   Schnater, JM, Bruder, E, Bertschin, S*, et al.* Subcutaneous and intrahepatic growth of human hepatoblastoma in immunodeficient mice. *J Hepatol*. 2006; **45**(3): 377-86.

17.   Chen, KF, Lai, YY, Sun, HS*, et al.* Transcriptional repression of human cad gene by hypoxia inducible factor-1alpha. *Nucleic Acids Res*. 2005; **33**(16): 5190-8.

18.   Cole, LK, Vance, JE, Vance, DE. Phosphatidylcholine biosynthesis and lipoprotein metabolism.

Biochim Biophys Acta. 2012; **1821**(5): 754-61.

19.   Cui, L, Lee, YH, Kumar, Y*, et al.* Serum metabolome and lipidome changes in adult patients with primary dengue infection. *PLoS Negl Trop Dis*. 2013; **7**(8): e2373.

20.   Ferrario, M, Cambiaghi, A, Brunelli, L*, et al.* Mortality prediction in patients with severe septic shock: a pilot study using a target metabolomics approach. *Sci Rep*. 2016; **6**: 20391.

21.   Park, DW, Kwak, DS, Park, YY*, et al.* Impact of serial measurements of lysophosphatidylcholine on 28-day mortality prediction in patients admitted to the intensive care unit with severe sepsis or septic shock. *J Crit Care*. 2014; **29**(5): 882 e5-11.

22.   Taylor, LA, Arends, J, Hodina, AK*, et al.* Plasma lyso-phosphatidylcholine concentration is decreased in cancer patients with weight loss and activated inflammatory status. *Lipids Health Dis*. 2007; **6**: 17.

23.   Chi, Z, Wang, ZP, Wang, GY*, et al.* Microbial biosynthesis and secretion of l-malic acid and its applications. *Crit Rev Biotechnol*. 2016; **36**(1): 99-107.

24.   Qiang, F. Effect of Malate-oligosaccharide Solution on Antioxidant Capacity of Endurance Athletes. *Open Biomed Eng J*. 2015; **9**: 326-9.

25.   Veech, RL. A humble hexose monophosphate pathway metabolite regulates short- and long-term control of lipogenesis. *Proc Natl Acad Sci U S A*. 2003; **100**(10): 5578-80.

26.   Shaeri, J, Wright, I, Rathbone, EB*, et al.* Characterization of enzymatic D-xylulose 5-phosphate synthesis. *Biotechnol Bioeng*. 2008; **101**(4): 761-7.

27.   Nakayama, Y, Kinoshita, A, Tomita, M. Dynamic simulation of red blood cell metabolism and its application to the analysis of a pathological condition. *Theor Biol Med Model*. 2005; **2**: 18.

28.   Kabashima, T, Kawaguchi, T, Wadzinski, BE*, et al.* Xylulose 5-phosphate mediates glucose-induced lipogenesis by xylulose 5-phosphate-activated protein phosphatase in rat liver. *Proc Natl Acad Sci U S A*. 2003; **100**(9): 5107-12.

29.   Jacobs, BAW, Snoeren, N, Samim, M*, et al.* The impact of liver resection on the dihydrouracil:uracil plasma ratio in patients with colorectal liver metastases. *Eur J Clin Pharmacol*. 2018; **74**(6): 737-44.

30.   Antonioli, L, Pacher, P, Vizi, ES*, et al.* CD39 and CD73 in immunity and inflammation. *Trends Mol Med*. 2013; **19**(6): 355-67.

31.   Glycerol-3-phosphate cytidylyltransferase. In: Schomburg, D, Schomburg, I, Chang, A (eds.). *Springer Handbook of Enzymes*. Berlin, Heidelberg: Springer Berlin Heidelberg; 2007. 404-11.

32.   Chanda, B, Xia, Y, Mandal, MK*, et al.* Glycerol-3-phosphate is a critical mobile inducer of systemic immunity in plants. *Nat Genet*. 2011; **43**(5): 421-7.

33.   Thaker, SK, Ch'ng, J, Christofk, HR. Viral hijacking of cellular metabolism. *BMC Biol*. 2019; **17**(1): 59.

Figure 1. COVID-19 signatures in the plasma metabolome. Selected average plasma metabolite expression levels and associated *p* values for COVID-19 fatality patient group vs. healthy volunteer group (A), and severe or mild vs. healthy groups (B). F, fatalities, first, second, third and fourth samples, F1, F2, F3 and F4. S, severe patients, first and second samples, S1 and S2; M, mild patients, first and second samples, M1 and M2.

Figure 2. The metabolome KEGG enrichment analysis of COVID-19 patient plasma. (A-B) KEGG pathway analysis of DEMs shared in all the groups. The color of bubbles represents the value of adjusted *P* value, and the size of bubbles represents the number of counts (sorted by gene ratio). (C-D) KEGG pathway analysis of DEMs shared unique to the fatal groups.

Figure 3. The potential metabolomic biomarkers of COVID-19. The relative intensity for each metabolite. Each dot represents a patient sample, and each patient group is differently colored as indicated. F, fatalities; S, the patients with severe symptom; M, the patients with mild symptom; H, healthy volunteers. *$P<0.05$, **$P<0.01$.

Figure 4. COVID-19 signatures in the plasma lipidome. Selected average plasma lipid expression levels and associated p values for COVID-19 fatality group vs. healthy

volunteer group (A), and severe or mild vs. healthy groups (B). AA, arachidonic acid; BA, bile acid; CAR, carnitine; CE, cholesterol ester; Cer, ceramide; DG, diacylglycerides; TG, Triglycerides; FA, fatty acid; FFA, free fatty acids; LPA, lysophosphatidic acid; PC, phosphatidylcholine; LPC, lysophosphatidylcholine; PE, phosphatidylethanolamine; LPE, lysophosphatidyl ethanolamine; LPG, lysophosphatidylglycerol; PI, phosphatidylinositol; PS, phosphatidylserine; LPO, lipid peroxide.

Figure 5. The lipidome KEGG enrichment analysis of COVID-19 patients. (A-B) KEGG pathway analysis of DEIs shared in all the groups. The color of bubbles represents the value of adjusted P value, and the size of bubbles represents the number of counts (sorted by gene ratio). (C-D) KEGG pathway analysis of DEIs shared unique to the fatal groups.

Figure 6. The potential lipidomic biomarkers of COVID-19. The relative intensity for each lipid. Each dot represents a patient sample, and each patient group is differently colored as indicated. F, fatalities; S, the patients with severe symptom; M, the patients with mild symptom; H, healthy volunteers. *P<0.05, **P<0.01.

Figure 7. ROC curve analysis for the predictive power of biomarkers for distinguishing COVID-19 patients and healthy controls. (A) ROC curve analysis for the predictive power of each plasma metabolite for distinguishing COVID-19 groups

from healthy controls; (B) ROC curve analysis for the predictive power of combined five plasma metabolites for distinguishing fatal group from mild group; (C) ROC curve analysis for the predictive power of combined five plasma metabolites for distinguishing severe group from mild group; (D) ROC curve analysis for the predictive power of combined five plasma metabolites for distinguishing fatal group from severe group; (E) ROC curve analysis for the predictive power of combined down-regulated lipids for distinguishing fatal group from healthy controls; (F) ROC curve analysis for the predictive power of combined up-regulated lipids for distinguishing fatal group from healthy controls.

Table 1. Multivariable Analysis of the Associations of Age and Gender with COVID-19.

Variables	Odds Ratio	95% CI	P-value [a]
Age	0.95	(0.89,1.01)	0.14
Gender	3.67	(0.80, 20.86)	0.11

[a] P values were calculated using the 2-sided test.

Supplementary Data

Supplementary methods and materials

Supplementary Figure S1-S4

Supplementary Table S1-S15

Methods and Materials

Ethics and Human Subjects

All work performed in this study was approved by the Wuhan Jinyintan Hospital Ethics Committee and written informed consent was obtained from patients. Diagnosis of SARS-CoV-2 infection was based on the New Coronavirus Pneumonia Prevention and Control Program (6th edition) published by the National Health Commission of China. Healthy subjects were recruited from healthcare workers and laboratory workers at Wuhan Jinyintan Hospital and Wuhan Institute of Virology, CAS, none of whom had previously experienced SARS-CoV-2 infection.

Patient Samples

SARS-CoV-2-positive patients were enrolled in the study after diagnosis. Blood sample (≤3mL) from fatal COVID-19 patients were collected over the course of their disease at intervals of 3-5 days. Blood sample (≤3mL) from the patients with severe and mild symptoms were collected at the time when the disease were most serious (3-7 days after hospitalization) and the time before discharge. Single samples were collected from healthy volunteers recruited from healthcare workers and laboratory workers at Wuhan Jinyintan Hospital and Wuhan Institute of Virology. The throat swabs and serological testing of healthy volunteers were negative for SARS-CoV-2. All blood samples were collected after fasting overnight and by potassium-EDTA blood collection tubes. All samples used in this study are described in Table S1. All the blood samples were treated according to the biocontainment procedures of the

processing of SARS-CoV-2-positive sample.

Methods for extraction of hydrophilic and hydrophobic compounds

To analysis hydrophilic compounds, sample was thawed on ice, 3 volumes of ice-cold methanol was added to 1 volume of plasma/serum, whirled the mixture for 3 min and centrifuge it with 12,000 g at 4°C for 10 min. Then the supernatant was centrifuged at 12,000 g at 4°C for 5 min, and then collected the supernatant and subjected them to LC-MS/MS analysis.

To analysis hydrophobic compounds, sample was thawed on ice, whirl around 10 s, and then centrifuge it with 3000 g at 4°C for 5 min. Take 50 µL of one sample and homogenized it with 1mL mixture (include methanol，MTBE and internal standard mixture). Whirled the mixture for 2 min. Then added 500 µL of water and whirled the mixture for 1 min, and centrifuged it with 12,000 g at 4°C for 10 min. Extracted 500 µL supernatant and concentrated it. Dissolved powder with 100 µL mobile phase B and subjected to LC-MS/MS analysis.

UPLC conditions of hydrophilic and hydrophobic compounds

The sample extracts of hydrophilic compounds were analyzed using an LC-ESI-MS/MS system (UPLC, Shim-pack UFLC SHIMADZU CBM A system, MS, QTRAP® 6500+ System). The samples were injected onto a Waters HSS T3 column (1.8 µm, 2.1 mm×100 mm). Column temperature, flow rate and injection volume were set 40°C, 0.4 mL/min and 2µL, respectively. Mobile phase was composed of water containing 0.1% formic acid (A) and acetonitrile containing 0.1% formic acid (B). The gradient program initiated from 5% B increased to 90% B in 11.0 min, and held for 1 min and then decreased 5% B for re-equilibrium.

The sample extracts of hydrophobic compounds were analyzed using an LC-ESI-MS/MS system (UPLC, Shim-pack UFLC SHIMADZU CBM A system, MS, QTRAP® 6500+ System). The samples were injected onto a Thermo C30 column (2.6 µm, 2.1 mm×100 mm). Mobile phase was composed of acetonitrile/water (60/40, v/v) containing 0.04% acetic acid and 5 mmol/L ammonium formate (A) and

acetonitrile/isopropanol (10/90, v/v) containing 0.04% acetic acid and 5 mmol/L ammonium formate (B). The gradient program initiated from 20%B to 50% in 3 min, to 65% in 2 min, to 75% 4 min and to 90% in 6.5 min. The flow rate, column temperature and injection volume were set 0.35 ml/min, 45°C and 2μL, respectively. The effluent was alternatively connected to an ESI-triple quadrupole-linear ion trap (QTRAP)-MS.

ESI-Q TRAP-MS/MS of hydrophilic and hydrophobic compounds

LIT and triple quadrupole (QQQ) scans were acquired on a triple quadrupole-linear ion trap mass spectrometer (QTRAP), QTRAP® LC-MS/MS System, equipped with an ESI Turbo Ion-Spray interface, operating in positive and negative ion modes and controlled by Analyst 1.6.3 software (Sciex). The ESI source operation parameters were as follows: ion source, turbo spray; source temperature 550 °C; ion spray voltage (IS) 5500 V in positive ion mode (or -4500 V in negative ion mode); ion source gas I (GSI), gas II (GSII), curtain gas (CUR) were set at 45, 55, and 35 psi, respectively; the collision gas (CAD) was medium. Instrument tuning and mass calibration were performed with 10 and 100 μmol/L polypropylene glycol solutions in QQQ and LIT modes, respectively. QQQ scans were acquired as MRM experiments with collision gas (nitrogen) set to 5 psi. Declustering potential (DP) and collision energy (CE) for individual MRM transitions was done with further DP and CE optimization. A specific set of MRM transitions were monitored for each period according to the metabolites within this period. Each sample analysis was conducted by both positive and negative ion modes, and the MRM transitions were listed in Table S15.

Plasma mentalities and lipids data analysis

The mass spectrum data were processed by Software Analyst 1.6.3. The repeatability of metabolite extraction and detection can be judged by total ion current (TIC) and multi peak MRM. Based on home-made MWDB (metadata database) and other databases, qualitative analysis of information and secondary general data was

carried out according to retention time (RT) and mass-to-charge ratio. Metabolite structure analysis referred to some existing mass spectrometry public databases, mainly including massbank (http://www.massbank.jp/), knapsack (http://kanaya.naist.jp/knapsack/), HMDB (http://www.hmdb.ca/), and Metlin (http://metlin.scripps.edu/index.php). The metabolite identification was conduced by reference standards in our home-made database and public databases, and more detailed information is listed in Table S14.

For the quality control (QC) of metabolomic analysis, we pipette 10 μL of each sample to pool a QC sample. When running sample sets on column, one QC sample was injected after 10 samples in the sequence. Metabolite quantification was accomplished by using multiple reaction monitoring (MRM) of triple quadrupole mass spectrometry. Opened the mass spectrum file under the sample machine with multiquant software to integrated and calibrated the chromatographic peaks. The peak area of each chromatographic peak represented the relative content of the corresponding substance. Finally, exported all the integral data of chromatographic peak area to save, and used the self-built software package to remove the positive and negative ions of metabolites. We calculated coefficient of variation (CV) values of the metabolites in QC samples, and removed the metabolites whose CV values were larger than 0.5. When the metabolites were detected in both positive and negative ionization modes, we removed the metabolites with larger CVs in either positive or negative mode.

To maximize identification of differences in metabolic profiles between groups, the orthogonal projection to latent structure discriminant analysis (OPLS-DA) model was applied using the MetaboAnalyst online tool (https://www.metaboanalyst.ca/). The OPLS-DA model was evaluated with the relevant R^2 and Q^2. And we used the permutation to assess the risk that the current OPLS-DA model is spurious.

Pathway Enrichment

We used the Kyoto Encyclopedia of Genes and Genomes (KEGG) database (http://www.genome.jp/kegg/) to analyze the KEGG pathway enrichment to identify

highly enriched metabolic pathways in differential metabolites or lipids. The p-value <0.05 was considered significantly changing pathways and was used for subsequent analysis.

Statistically Processed Datasets

Plasma metabolomics and lipidomics datasets (including fold-change and *P*-values for various group comparisons) are provided in Table S4-S5 and S8-S9. Plasma metabolomics pathway enrichment are provided in Table S6-S7. Plasma lipidomic pathway enrichment are provided in Table S10-S11.

Raw Data

All raw LC-MS/MS data has been deposited to the iProX under the accession number: PXD018307.

Statistics.

The orthogonal-projection-to-latent-structure–discriminant-analysis (OPLS-DA) model was applied using R package "MetaboAnalyst". And the OPLS-DA model verification was performed by a permutation test repeated 200 times. In general, $P < 0.05$ indicated the available OPLS-DA model. Student t test and fold change were also applied to measure the significance of each metabolite. Statistical significance was analyzed using one-tailed Student's t test or Fisher's exact test, and $P < 0.05$ was considered to be statistically significant. The P value was corrected for multiple testing via false-discovery rate (FDR) using the Benjamini-Hochberg method.

Logistic regression analysis and receiver operating characteristic (ROC) analysis were used for diagnosis of COVID-19 patient samples and healthy subjects. ROC curves were utilized to evaluate the biomarkers performance. It was conducted applying R software version 3.6.1. (R Foundation for Statistical Computing, Vienna, Austria).

Supplementary Figure legends

Figure S1. The orthogonal projection to latent structure discriminant analysis (OPLS-DA) showed the best possible discrimination of metabolites between fatal COVID-19 patients and healthy people as indicated. The x-axis represents the prediction component that shows differences between groups, and the y-axis represents the orthogonal component differences within the group. R2 represents goodness of fit, Q2 represents goodness of prediction, and *P* value shows the significance level of the model (x-axis = predictive components, y-axis = orthogonal component).

Figure S2. The OPLS-DA showed the best possible discrimination of metabolites between severe or mild COVID-19 patients and healthy people as indicated. The x-axis represents the prediction component that shows differences between groups, and the y-axis represents the orthogonal component differences within the group. R2 represents goodness of fit, Q2 represents goodness of prediction, and *P* value shows the significance level of the model (x-axis = predictive components, y-axis = orthogonal component).

Figure S3. The OPLS-DA showed the best possible discrimination of lipids between fatal COVID-19 patients and healthy people as indicated. The x-axis represents the prediction component that shows differences between groups, and the y-axis represents the orthogonal component differences within the group. R2 represents goodness of fit, Q2 represents goodness of prediction, and *P* value shows the significance level of the model (x-axis = predictive components, y-axis = orthogonal component).

Figure S4. The OPLS-DA showed the best possible discrimination of lipids between severe or mild COVID-19 patients and healthy people as indicated. The x-axis represents the prediction component that shows differences between groups, and the y-axis represents the orthogonal component differences within the group. R2 represents goodness of fit, Q2 represents goodness of prediction, and *P* value shows the significance level of the model (x-axis = predictive components, y-axis = orthogonal component).

Table S1. Study design and patients

	Fatal (F)				Severe (S)		Mild (M)		Healthy (H)
	T1	**T2**	**T3**	**T4**	**T1**	**T2**	**T1**	**T2**	**H**
Onset to hospitalization	1. 8	5.1	10.1	14.8	5. 4	15.4	5.2	13	NA
Days (SD)	(0.4)	(0.3)	(0.3)	(1.2)	(3.1)	(4.8)	(0.6)	(0)	NA
Sex									
Female		5				8		9	5
Male		4				3		5	5
Age		64.6				57.4		45.9	48.7
Mean (SD)		(8.5)				(12.5)		(11.8)	(9.6)
Patients		9				11		14	10
Sample number		(36)				(22)		(28)	(10)

Table S2. Overview of total changed metaboites

Total metaboites (431)	Metabolites (p <0.05)	Up-regulated	wn-regula	ax (Log$_2$F	Min (Log$_2$FC)
F1 vs. H	87	4	83	2.17	-5.19
F2 vs. H	164	19	145	1.95	-8.98
F3 vs. H	172	45	127	2.6	-8.66
F4 vs. H	162	51	111	2.87	-6.67
S1 vs. H	142	23	119	1.73	-6.79
S2 vs. H	154	24	130	1.68	-7.03
M1 vs. H	190	28	162	1.36	-5.58
M2 vs. H	203	49	154	1.97	-8.29

Table S2. Overview of total changed lipids

Total lipid (698)	Lipids (p <0.05)	Up-regulated	Down-regulated	Max (Log$_2$FC)	Min (Log$_2$FC)
F1 vs. H	255	111	144	4.54	-3.02
F2 vs. H	203	134	69	4.2	-3.6
F3 vs. H	221	135	86	4.23	-3.6
F4 vs. H	248	152	96	2.29	-4.1
S1 vs. H	157	57	100	5.37	-4.08
S2 vs. H	158	104	54	4.76	-3.78
M1 vs. H	120	82	38	4.44	-4.23
M2 vs. H	127	93	34	5.61	-3.47

Table S4. Metabolomics data of F vs H

Compounds	Class	Log₂ FC F1/H	F2/H	F3/H	F4/H	P value F1/H-P	F2/H-P	F3/H-P	F4/H-P	FDR F1/H-FDR	F2/H-FDR	F3/H-FDR	F4/H-FDR
N-Acetylmethionine	Amino acid metabolome	0.415994917	0.384180519	-0.520902749	1.472418955	0.2871537	0.34377689	0.17238011	0.02486072	0.357697	0.396171	0.253569	0.098111
5-Oxoproline	Amino acid metabolome	-0.447918969	-0.371686393	-0.602655136	-1.001115079	0.00443867	0.01061575	0.00112247	3.2844E-05	0.037522	0.051512	0.015572	0.002827
H-Homoarg-Oh	Amino acid metabolome	-0.280135404	-0.584682436	-0.563126941	-1.052391897	0.11015728	0.00797714	0.05488502	0.00111958	0.203767	0.045225	0.132896	0.014459
L-Dopa	Amino acid metabolome	-2.441226333	-0.235731174	0.0001691	-1.054779217	0.00191993	0.38296416	0.49991836	0.03253759	0.021776	0.419807	0.499918	0.108711
L-Cysteine	Amino acid metabolome	-1.071199628	-1.439037259	-0.972533476	-1.063727456	0.0008726	0.00104244	0.00500835	0.00082683	0.014238	0.004093	0.040728	0.013199
3-Hydroxykynurenine	Amino acid metabolome	-1.177065918	-0.575286888	-1.122272826	-1.250957275	0.04570095	0.16356476	0.05331719	0.04320105	0.126145	0.249241	0.130567	0.122452
N-Alpha-Acetyl-L-Asparagine	Amino acid metabolome	-2.106915553	-1.969521205	-1.868188579	-1.28968066	0.00110143	0.00137539	0.00201758	0.02126469	0.014485	0.013556	0.022147	0.088981
N-Amidino-L-Aspartate	Amino acid metabolome	-2.260634457	-2.01719017	-2.629166494	-1.793526857	0.02105796	0.0263016	0.01654673	0.03175842	0.086907	0.092163	0.074333	0.106937
N-Acetylneuraminic Acid	Amino acid metabolome	-1.660029412	-1.93638719	-2.437826541	-1.863045695	0.00357033	0.00223934	0.00122678	0.0025072	0.033452	0.019303	0.016523	0.027015
L-Alanyl-L-Lysine	Amino acid metabolome	-1.140709361	-1.428848574	-1.516403339	-1.875582527	0.07409744	0.04420242	0.03999528	0.02602591	0.168974	0.11907	0.109104	0.099267
N-Acetyl-L-Leucine	Amino acid metabolome	-1.762353717	-2.309423849	-1.782895081	-1.949248479	0.00015516	0.00010697	0.00010429	0.00010429	0.007268	0.002581	0.005123	0.005619
L-Cystine	Amino acid metabolome	-0.806890274	-0.976201639	-1.795300507	-2.469899382	0.13856428	0.10713298	0.03547641	0.02068592	0.234201	0.194828	0.103146	0.088319
(5-L-Glutamyl)-L-Amino Acid	Amino acid metabolome	-1.715117389	-2.255227468	-2.261791293	-2.71761163	0.06058035	0.04127386	0.0413158	0.03293674	0.149986	0.113306	0.110603	0.109198
Sarcosine	Amino acid metabolome	-3.612929377	-1.113695858	-1.641170407	-3.051463298	5.9217E-05	0.02179128	0.00293875	7.778E-05	0.005301	0.082296	0.029315	0.00479
L-Aspartic Acid	Amino acid metabolome	-2.916577992	-3.291196182	-2.606249992	-3.466167213	0.00105208	0.00086573	0.00132824	0.00080486	0.014485	0.010403	0.017348	0.013199
N-Glycyl-L-Leucine	Amino acid metabolome	-3.008074611	-3.067149388	-3.778841704	-3.725162489	0.03744406	0.0367998	0.03074046	0.03108619	0.114457	0.107896	0.096709	0.106937
Nα-Acetyl-L-Arginine	Amino acid metabolome	-3.292069569	-3.325872506	-4.003237843	-4.044157808	0.00139963	0.00135444	0.00110141	0.00108834	0.017235	0.013556	0.015572	0.014459
O-Acetyl-L-serine	Amino acid metabolome	-3.234102794	-3.124768019	-4.045101323	-2.95324936	0.00025287	0.00024919	0.0001859	0.00029571	0.007268	0.004882	0.006677	0.007966
Uridine triphosphate (UTP)	Nucleotide metabolome	-2.352669171	-1.108219394	0.698174055	2.870307136	0.00881366	0.06646519	0.22913253	0.03822944	0.056697	0.151735	0.310554	0.116857
deoxyguanosine 5'-monophosphate	Nucleotide metabolome	1.506002537	0.465477066	0.749780452	1.643067895	0.0430234	0.17435193	0.06058304	0.02288414	0.123621	0.258233	0.139633	0.094837
Hypoxanthine	Nucleotide metabolome	-0.037891104	0.596263602	0.444552613	1.519397387	0.47215743	0.01246902	0.08535843	0.00591071	0.488009	0.057172	0.163331	0.044693
3'-Aenylic Acid	Nucleotide metabolome	1.392182494	0.599545275	0.44272121	1.267302783	0.0756399	0.1565078	0.16931641	0.03812101	0.169796	0.243914	0.251796	0.116857
5-Methyluridine	Nucleotide metabolome	0.772244296	0.763794199	1.568552482	1.231203344	0.01544519	0.03261419	0.00108558	0.0002229	0.070818	0.100405	0.015572	0.00739
5-Methylcytosine	Nucleotide metabolome	-0.522802704	-0.525288643	-0.436557512	-1.247869653	0.03693815	0.14560266	0.09640043	0.00117853	0.113717	0.235036	0.173843	0.014513
Guanosine Monophosphate	Nucleotide metabolome	-1.01085111	-2.375810208	-1.823182945	-1.709805764	0.01087734	0.00013579	0.00038042	0.00100876	0.060875	0.004093	0.007808	0.014459
Dihydrouracil	Nucleotide metabolome	-2.140363657	-1.374596288	-2.358028205	-1.926207632	0.00048212	0.00417724	0.00035052	0.0006581	0.01148	0.029515	0.007733	0.012332
B-Pseudouridine	Nucleotide metabolome	-2.895100616	-2.810705713	-2.23918617	-2.517156789	0.02662211	0.02760949	0.03716515	0.0315478	0.095923	0.094442	0.105511	0.106937
Cis-Aconitic Acid	Organic Acid And Its Derivatives	-1.120802486	-0.857782801	-0.875442375	-1.447042979	0.00407701	0.0154246	0.01187099	0.00130409	0.035352	0.065176	0.068234	0.015613
Citramalic Acid	Organic Acid And Its Derivatives	-3.548147156	-3.183793648	-3.326909404	-3.715308677	0.02789946	0.03079973	0.02950419	0.02689142	0.097342	0.099065	0.095782	0.100784
Malic Acid	Organic Acid And Its Derivatives	-3.206838386	-3.563824852	-3.227371977	-5.178816299	0.01140767	0.01007657	0.01143676	0.00755024	0.061459	0.0505	0.062342	0.052433
N1-Acetylspermine	Organic Acid And Its Derivatives	1.018200609	1.116510939	1.753830238	1.935242615	0.08698112	0.09454163	0.03883918	0.04390691	0.183606	0.185151	0.107306	0.122882
N-lactoyl-phenylalanine	Organic Acid And Its Derivatives	0.284114294	0.903020696	1.471939376	1.557708606	0.18099055	0.02899227	0.01866529	0.011404	0.270857	0.095447	0.078104	0.014459
Mandelic Acid	Organic Acid And Its Derivatives	0.097443856	1.720011942	1.64699748	1.321684741	0.43315083	0.15277905	0.00444279	0.02881815	0.466875	0.242087	0.038018	0.101808
3-Hydroxy-3-Methyl Butyric Acid	Organic Acid And Its Derivatives	0.577803772	0.939790635	1.253056418	1.166968551	0.06686681	0.05853304	0.00717393	0.00043941	0.159224	0.144987	0.050091	0.008712
Phenyllactate (Pla)	Organic Acid And Its Derivatives	-0.069363859	0.558788547	1.136634978	1.141881586	0.37732298	0.07221966	0.01498654	0.00016516	0.423506	0.158914	0.072153	0.006596
4-Hydroxy-2-Oxoglutaric Acid	Organic Acid And Its Derivatives	-0.68396317	-0.910530846	-1.11941989	-1.305520833	0.15069856	0.07249327	0.04718325	0.02597414	0.245526	0.158914	0.119399	0.099267
Indoxylsulfuric acid	Organic Acid And Its Derivatives	-0.920873052	-1.457753371	-0.981937431	-1.483662536	0.0922304	0.03739765	0.14010809	0.00887305	0.187506	0.10887	0.225036	0.057079
Dl-2-Aminooctanoic Acid	Organic Acid And Its Derivatives	-1.244598672	-1.255631851	-1.282523616	-1.497514137	0.01349284	0.01360307	0.01267284	0.00732938	0.067488	0.059826	0.06962	0.052433
2-Aminoethanesulfinic Acid	Organic Acid And Its Derivatives	-1.280009315	-1.496471445	-1.144544201	-1.758349791	0.01853787	0.01157806	0.02491116	0.00773289	0.081247	0.055742	0.089759	0.052433
L-Methionine Sulfoximine	Organic Acid And Its Derivatives	-2.307100912	-2.509294467	-2.362623912	-2.665328985	0.02915224	0.02594397	0.02826969	0.0238819	0.098161	0.092163	0.093835	0.096197
2-Hydroxyisocaproic Acid	Organic Acid And Its Derivatives	-3.790464382	-3.166002961	-3.029558807	-2.805247946	0.03351073	0.03866299	0.04024942	0.04346848	0.108595	0.110356	0.109104	0.122452
Phenylpyruvic Acid	Organic Acid And Its Derivatives	-2.737370388	-2.69576858	-3.528189451	-3.247680964	0.04058986	0.04101646	0.03129708	0.03379101	0.119823	0.113306	0.097747	0.110333
Ergothioneine	Organic Acid And Its Derivatives	-3.448930308	-3.374926884	-3.89268884	-3.512533296	0.02541384	0.02195826	0.02297446	0.02503998	0.093766	0.082296	0.085196	0.098111
Carbamoyl phosphate	Organic Acid And Its Derivatives	-1.526632777	-2.042064967	-2.666074024	-3.666841326	0.00593383	0.00334522	0.00085863	0.00049831	0.042625	0.025746	0.013217	0.010227
Isonicotinic acid	Organic Acid And Its Derivatives	-3.879547296	-5.648610448	-4.955527493	-4.637430056	0.01503823	0.01206104	0.01276009	0.01323711	0.070451	0.055896	0.065196	0.098111
Acetaminophen Glucuronide	Carbohydrate metabolome	-0.230924481	0.196090345	1.149390556	1.676663834	0.30909692	0.3277224	0.06419961	0.03924157	0.37075	0.386982	0.141634	0.118274
L-Erythrulose	Carbohydrate metabolome	-0.076489985	0.154721829	0.988749157	1.020589037	0.39538228	0.39519967	0.02133869	0.00547931	0.437049	0.427967	0.081959	0.042666
Lactose	Carbohydrate metabolome	-2.23635777	-1.623656778	-2.314813049	-1.395327023	0.00765052	0.0158764	0.00717217	0.02311053	0.051521	0.066203	0.050091	0.094863
D-Glucoronic Acid	Carbohydrate metabolome	-2.443511932	-1.447618479	-1.312332069	-1.503869652	0.01093825	0.03308339	0.04009403	0.02970504	0.060875	0.109598	0.109104	0.104459
Gluconic Acid	Carbohydrate metabolome	-2.016004597	-1.887481838	-1.60319055	-1.532762172	0.01115806	0.01294232	0.02054185	0.02074689	0.060875	0.058717	0.080933	0.088319
L-Gulonic-γ-Lactone	Carbohydrate metabolome	-1.393766351	-1.511403277	-1.550709624	-1.700103805	0.02379292	0.01921342	0.01821003	0.01475217	0.09156	0.075972	0.077626	0.097913
D-Xylulose 5-phosphate	Carbohydrate metabolome	-1.110634663	-1.931070057	-1.509001431	-1.81924148	0.00058612	9.4071E-07	1.3602E-06	9.2166E-07	0.01148	0.000135	0.000195	0.000188
L-Rhamnose	Carbohydrate metabolome	-0.402516994	-1.4398494	-1.2662848	-2.016649444	0.2735613	0.03257786	0.02474441	0.0087337	0.344751	0.276598	0.08793	0.05243
D-Mannitol	Carbohydrate metabolome	-4.200787431	-4.48231841	-3.579845329	-2.116327027	0.00154245	0.00145919	0.00185159	0.01029908	0.018467	0.013976	0.021001	0.063413
L-Fucose	Carbohydrate metabolome	-0.630581712	-1.155422959	-1.929328553	-3.013742894	0.19591725	0.07263608	0.01785314	0.00778594	0.283357	0.158914	0.076947	0.052433
1,5-Anhydro-D-Glucitol	Carbohydrate metabolome	-1.526155949	-1.569348282	-2.257159908	-3.086229903	0.04243338	0.04086474	0.0207695	0.01324679	0.122744	0.113306	0.080933	0.070913
Scyllo inositol	Alcohol	-0.05009625	0.079143382	1.155304021	1.706850263	0.46760834	0.44392587	0.0438122	0.03673148	0.485528	0.461041	0.113753	0.116212
2-Methyl-5-nitroimidazole-1-ethanol	Alcohol	2.169949698	0.154721829	1.664315059	1.410794066	0.03545064	0.00860949	0.02647556	0.00455425	0.111527	0.046384	0.090064	0.070913
Norambreinolide	Lactone	-0.714199887	-0.744741143	-0.701920366	-1.166068593	0.02549419	0.0363593	0.03197217	0.00287439	0.093766	0.107335	0.098959	0.028871
1-Aminopropan-2-ol	Alcohol	-1.491288496	-1.788290069	-1.299935025	-2.151934585	0.00719931	0.00434813	0.0326038	0.0007028	0.05058	0.030183	0.098959	0.012576
Isoxanthopterin	Pteridines and derivatives	-2.531334118	-3.01890695	-2.600038606	-2.676187792	0.02866832	0.02297173	0.02753016	0.02651252	0.097995	0.085352	0.092699	0.100236
Cyclohexylamine	Amines	-0.553781145	0.232729775	0.727100227	-2.743376041	0.22517876	0.00034456	0.00041044	0.00030197	0.311064	0.00594	0.008041	0.009529
Putrescine	Polyamine	-2.844967201	-2.659468757	-2.703403291	-2.852560167	4.0929E-08	4.4946E-08	4.0817E-08	5.0504E-08	1.76E-05	9.68E-06	8.79E-06	2.18E-05
Serotonin	Indole And Its Derivatives	-2.822462604	-3.883906002	-3.800300115	-2.874339687	0.02887563	0.0201719	0.02084342	0.02812473	0.097995	0.078637	0.080933	0.101808
Neopterin	Pteridines and derivatives	-2.787512544	-3.036663962	-2.816184942	-3.22401401	0.00018005	0.00017464	0.00016523	0.00015409	0.007268	0.004377	0.006474	0.006596
Indole-3-acetamide	Indole And Its Derivatives	-3.731376522	-3.921986967	-3.106105716	-3.517754908	0.00506415	0.00480614	0.00641108	0.00541906	0.038595	0.032063	0.049438	0.042666
2-Picoline	Pyridine And Pyridine Derivatives	-2.362221327	-2.820975029	-3.261610435	-3.574343308	0.02721545	0.02003866	0.01667657	0.01515249	0.096941	0.077183	0.074333	0.07168
Sn-Glycero-3-Phosphocholine	Cholines	-4.973711277	-5.332667589	-5.307573787	-4.824307576	0.03674479	0.03587996	0.03593561	0.03718428	0.113717	0.10665	0.101233	0.116857
δ-Valerolactam	Pyridine And Pyridine Derivatives	-0.639148423	-4.157411758	-4.239463719	-5.334100861	0.22300092	0.00054739	0.00054706	0.00046065	0.310781	0.007864	0.009824	0.009927
3-Indolepropionic Acid	Indole And Its Derivatives	-4.929557423	-7.256453584	-8.662062132	-6.674774772	0.00032406	0.00028214	0.0002748	0.00028835	0.008735	0.005287	0.006762	0.007966
Estrone	Hormones	-0.145457338	0.019546309	0.857122614	1.206205783	0.35634342	0.48458731	0.10557413	0.04553762	0.406307	0.490275	0.185875	0.12422
L-Thyroxine	Hormones	-0.188117556	-0.44077217	-0.64945803	-1.007003814	0.02772902	0.00356096	1.992E-05	1.6393E-05	0.097342	0.026305	0.001429	0.001767
octadecanedioate (C18)	Hydrocarbon derivative	-0.118078167	0.393535189	1.354421113	-1.109906788	0.40389557	0.29718643	0.17598932	0.01295613	0.440837	0.361829	0.256255	0.070913
3,3',5-Triiodo-L-Thyronine	Hormones	-1.279338406	-1.679313098	-1.845531732	-1.492671405	9.3271E-08	3.319E-09	1.6692E-10	1.309E-06	2.01E-05	1.43E-06	7.2E-08	0.000188
Orotic Acid	CoOthersEnzyme Factor & vitamin	-1.610007577	-1.353042967	-1.629173256	-1.908832552	0.01182114	0.01812697	0.01141437	0.00736645	0.062208	0.073016	0.067342	0.052433
Glycyrrhetinic acid	Terpenoid	-1.349908869	0.243520646	-1.613806534	-2.207272021	0.08882127	0.42117632	0.07064852	0.04458258	0.184048	0.443396	0.147099	0.123174
1,2-Dichloroethane	Hydrocarbon derivative	-5.187816921	-5.223361669	-5.246237585	-5.295740786	0.04374182	0.04364953	0.0435911	0.04346904	0.124031	0.119069	0.113753	0.122452
Allantoin	others	-4.395176642	-4.186285446	-4.03701915	-4.969576518	0.00022164	0.00023191	0.00024009	0.00020487	0.007268	0.00476	0.007427	0.007358

Table S5. Metabolomics data of S vs H and M vs H

Compounds	Class	Log₂ FC				P value				FDR			
		ST1/H	ST2/H	MT1/H	MT2/H	ST1/H-P	ST2/H-P	MT1/H-P	MT2/H-P	ST1/H-FDR	ST2/H-FDR	MT1/H-FDR	MT2/H-FDR
Phe-Phe	Amino Acid metabolome	-1.05906834	-1.22583751	-1.68646136	-1.11816052	0.004679	0.0014214	0.00019426	0.00181709	0.04358824	0.0139233	0.00272404	0.01118808
L-Cystathionine	Amino Acid metabolome	-1.75346445	-2.40892785	-2.40260195	-2.43224694	0.00173196	0.00069417	0.00065813	0.0006843	0.02132785	0.0085482	0.00578884	0.00508508
L-Dopa	Amino Acid metabolome	-2.29427823	-2.44310536	-2.31547106	-2.39848049	0.00220982	0.00190194	0.00214842	0.00199468	0.02645649	0.01821635	0.01341986	0.01206046
3-Hydroxykynurenine	Amino Acid metabolome	-1.79186548	-1.81585898	-1.22318025	-1.53950307	0.01956506	0.0188518	0.0442881	0.02732111	0.09849111	0.08149999	0.10458166	0.06967693
N-Alpha-Acetyl-L-Asparagine	Amino Acid metabolome	-2.55805256	-2.84708047	-3.13324874	-2.90126155	0.00064116	0.00053991	0.00045615	0.0004967	0.013159	0.00810579	0.00436889	0.00428153
N-Amidino-L-Aspartate	Amino Acid metabolome	-2.42070182	-2.44171792	-2.93976997	-1.89162518	0.01865745	0.01838336	0.01402385	0.02852099	0.09688387	0.08149999	0.04835422	0.07146829
N-Acetylneuraminic Acid	Amino Acid metabolome	-2.39427202	-2.81504141	-2.41293577	-2.3685697	0.00131501	0.00091455	0.0012841	0.00134177	0.01771153	0.01065329	0.00846764	0.00876215
L-Alanyl-L-Lysine	Amino Acid metabolome	-2.10859967	-2.80481191	-3.13307108	-2.75343848	0.02138691	0.01346366	0.01162127	0.01382661	0.10241953	0.06826868	0.04252109	0.04584052
N-Acetyl-L-Leucine	Amino Acid metabolome	-2.84733916	-3.00382764	-2.74393994	-3.22375948	3.0537E-05	2.8179E-05	3.2505E-05	2.6904E-05	0.00162131	0.00151813	0.00093397	0.00063699
L-Cystine	Amino Acid metabolome	-1.45739381	-1.2128957	-1.54212771	-1.09266731	0.04918087	0.06831089	0.04440474	0.08064969	0.15015933	0.16200898	0.10458166	0.1455814
Sarcosine	Amino Acid metabolome	-3.71742281	-3.61034573	-3.68508642	-3.08786364	5.7408E-05	6.0223E-05	5.8428E-05	6.106E-05	0.00218058	0.00196619	0.0013254	0.00119622
L-Aspartic Acid	Amino Acid metabolome	-5.09457755	-4.99466674	-4.64914552	-4.92532183	0.00053763	0.0005454	0.00057725	0.00055033	0.0115859	0.00810579	0.00529347	0.00440516
N-Glycyl-L-Leucine	Amino Acid metabolome	-3.58519868	-3.45770462	-3.09782118	-2.14804422	0.03196754	0.03288801	0.03624452	0.0547302	0.12517447	0.11074011	0.09029704	0.11167288
Nα-Acetyl-L-Arginine	Amino Acid metabolome	-4.14902549	-3.92033453	-3.95763022	-3.96718522	0.00105855	0.0011271	0.00111502	0.0011132	0.01573226	0.01180027	0.00809517	0.00773856
O-Acetyl-L-serine	Amino Acid metabolome	-4.64275323	-4.77679881	-4.43182731	-4.37768611	0.00017333	0.00017055	0.00018254	0.00018418	0.00462904	0.00411844	0.00272404	0.00212358
5'-Deoxy-5'-(Methylthio) Adeno	Nucleotide metabolome	-4.33756112	-4.51862491	-5.26895372	-5.0975755	6.4947E-05	6.3867E-05	5.6128E-05	5.7486E-05	0.00218058	0.00196619	0.0013254	0.00117983
Uridine triphosphate (UTP)	Nucleotide metabolome	-2.04084714	-1.57538364	-2.17406863	-1.99955254	0.01340991	0.02928856	0.01021172	0.01255587	0.07888482	0.10412017	0.03860747	0.04364176
Inosine	Nucleotide metabolome	-2.15733591	-1.86936199	-2.55037762	-2.57257078	0.03076683	0.03871004	0.0241337	0.02381901	0.12345615	0.11936908	0.07027749	0.06303615
Dihydrouracil	Nucleotide metabolome	-1.9166068	-0.85149498	-1.71069707	-1.80430668	0.00067919	0.08039193	0.00100123	0.00085537	0.01330601	0.1756365	0.00799132	0.00604369
B-Pseudouridine	Nucleotide metabolome	-2.87588338	-2.74390295	-3.10336524	-2.96865984	0.0268563	0.02840292	0.02464983	0.02586435	0.11459531	0.10412017	0.07027749	0.0667517
Succinic Acid	Organic Acid And Its Derivatives	-1.26588835	-1.31492814	-1.30385224	-1.1569683	3.3856E-05	0.00033037	1.0842E-05	3.4707E-05	0.00162131	0.00593295	0.00068072	0.00074794
Citramalic Acid	Organic Acid And Its Derivatives	-4.12579939	-4.24022408	-3.82168539	-3.73400652	0.02497068	0.02454446	0.02632056	0.0278008	0.11095221	0.09361649	0.07271898	0.06870365
Malic Acid	Organic Acid And Its Derivatives	-4.79582888	-4.29492432	-4.43537353	-4.21496517	0.00787589	0.00849239	0.00829052	0.00861254	0.05815933	0.05642869	0.03403061	0.03392794
(3-Methoxy-4-hydroxyphenyl)et	Organic Acid And Its Derivatives	-1.18864341	-1.22015497	-1.69220885	-1.2681763	0.00085867	0.00057151	3.029E-05	0.00226143	0.01382479	0.00821069	0.00093249	0.01277197
3-Methoxy-4-Hydroxyphenyleth	Organic Acid And Its Derivatives	-3.1816549	-3.04456093	-3.22145343	-1.01644672	2.6286E-08	7.498E-08	2.6824E-09	0.05291625	1.1329E-05	3.2316E-05	6.9822E-07	0.10964858
Chlorogenic Acid	Organic Acid And Its Derivatives	-2.45077631	-3.3370378	-2.15271448	-1.80268912	0.03345197	0.37568243	0.04019139	0.05151056	0.12627251	0.4294937	0.09898564	0.10777209
N'-Formylkynurenine	Organic Acid And Its Derivatives	-2.15871708	-2.34291063	-3.20625358	-1.60315939	0.00447591	0.00406984	0.00189247	0.01466406	0.04358824	0.03077373	0.01235616	0.04600378
4-Hydroxy-2-Oxoglutaric Acid	Organic Acid And Its Derivatives	-1.72476775	-1.87048899	-2.129502	-1.98912786	0.01353819	0.01173491	0.00823174	0.00997846	0.07888482	0.06702049	0.03403061	0.03786242
2-Aminoethanesulfonic Acid	Organic Acid And Its Derivatives	-2.01329404	-1.74297146	-1.74804235	-1.40494235	0.00542378	0.00585967	0.00766507	0.01345374	0.04770712	0.04140194	0.03270937	0.04565798
L-Methionine Sulfoximine	Organic Acid And Its Derivatives	-2.99568536	-3.04153693	-3.20484907	-3.25765697	0.02064383	0.0202872	0.01913397	0.01880763	0.09997181	0.08327411	0.05932907	0.05440329
2-Hydroxyisocaproic Acid	Organic Acid And Its Derivatives	-3.65182989	-3.68695653	-3.65881873	-3.90715702	0.03440263	0.0341794	0.0343559	0.03281746	0.12673106	0.11196622	0.08659295	0.07901857
Phenylpyruvic Acid	Organic Acid And Its Derivatives	-4.88666167	-4.97877429	-5.57541519	-6.02015642	0.02556932	0.02536695	0.02434985	0.02383966	0.11245282	0.09507092	0.07027749	0.06303615
Ergothioneine	Organic Acid And Its Derivatives	-4.14382146	-3.93661367	-4.47122515	-4.52810803	0.02196949	0.02277318	0.02096201	0.02081401	0.10405328	0.08911009	0.06362413	0.0579658
Carbamoyl phosphate	Organic Acid And Its Derivatives	-2.95772748	-3.14692934	-2.6558513	-1.92832878	0.00072114	0.00065168	0.00091588	0.00204818	0.0135135	0.00851135	0.00744804	0.01206046
Isonicotinic acid	Organic Acid And Its Derivatives	-4.46445661	-4.67356028	-4.85806258	-3.88968644	0.01354403	0.01316956	0.01288277	0.01502184	0.07888482	0.06757238	0.04514206	0.04657852
Xylose	Carbohydrate metabolome	-1.0535778	-0.93966636	-1.90435299	-1.5999677	0.04947245	0.0443139	0.00695623	0.0107245	0.15015933	0.12675593	0.03090861	0.03984708
Lactose	Carbohydrate metabolome	-2.33864995	-1.59596119	-2.22554951	-1.74121794	0.00698241	0.01700581	0.00799764	0.01725555	0.05373962	0.07881189	0.03346584	0.05200797
D-Glucoronic Acid	Carbohydrate metabolome	-2.6799046	-2.50784307	-3.24887496	-2.81334557	0.0093604	0.01045886	0.00705644	0.0086591	0.06613662	0.06533001	0.03103394	0.03392794
Gluconic Acid	Carbohydrate metabolome	-2.85259884	-1.95587227	-2.1851394	-2.15167591	0.0057068	0.01211333	0.00940973	0.01006128	0.04861878	0.06705363	0.03653687	0.03786242
L-Gulonic-γ-Lactone	Carbohydrate metabolome	-1.59401273	-1.74174734	-1.67023036	-1.71872069	0.01692661	0.01388157	0.01524971	0.01430647	0.09254256	0.06956925	0.05123981	0.04600378
D-Xylulose 5-phosphate	Carbohydrate metabolome	-1.444644	-1.05160009	-1.42366898	-0.96677257	2.329E-06	2.6262E-06	2.262E-06	2.6107E-05	0.00025096	0.00174591	0.00018865	0.00063699
L-Rhamnose	Carbohydrate metabolome	-2.93019633	-3.48254758	-2.80808161	-4.14458569	0.00404843	0.00312847	0.00436184	0.00256686	0.04358824	0.0254098	0.02332911	0.01400401
D-Mannitol	Carbohydrate metabolome	-5.40153652	-4.78256707	-5.5438931	-5.13857399	0.00128126	0.00138758	0.00126378	0.00132013	0.01771153	0.01390805	0.00864585	0.00875348
L-Fucose	Carbohydrate metabolome	-3.59766842	-4.05648469	-3.53633348	-5.07375555	0.00615817	0.00543627	0.00628495	0.00460585	0.0491513	0.03905057	0.02943371	0.02194888
1,5-Anhydro-D-Glucitol	Carbohydrate metabolome	-3.4542073	-3.12839242	-3.06713628	-5.04604577	0.01113901	0.01236342	0.01279778	0.00814965	0.0750143	0.06705363	0.04514206	0.03252316
2-Methyl-5-nitroimidazole-1-eth	Alcohol	1.733934443	1.678609625	1.360681696	1.968402856	0.00463457	0.00195199	4.4946E-05	4.6805E-06	0.04358824	0.01827065	0.00113835	0.0002951
Pulegone	Ketones	-5.30640569	-5.3068221	-4.5834145	-4.92088401	0.01725032	0.01724931	0.0184869	0.01782403	0.09293609	0.07908994	0.0581595	0.05212427
4-Pyridoxic Acid	Pyridine And Pyridine Derivatives	-1.59548	-1.5691076	-1.34550914	-1.4972066	0.00015571	0.00018943	0.00031723	0.00016468	0.00447415	0.00420137	0.00359807	0.00202794
Methyl Indole-3-Acetate	Indole And Its Derivatives	-1.92095722	-1.0571598	-2.03838744	-1.14229015	0.00135916	0.0011818	0.00112108	0.00745495	0.01775148	0.06702049	0.00809517	0.0306008
Dopamine	Polyamine	-1.42453376	-1.50217662	-1.72466544	-1.53733559	0.00082577	0.00067939	0.00042525	0.00063806	0.01382479	0.0085482	0.00421046	0.00482464
Isoxanthopterin	Pteridines and derivatives	-2.08614335	-2.46312989	-3.61471926	-2.21400031	0.0407124	0.02995569	0.01909292	0.03573903	0.13708629	0.10412017	0.05932907	0.08417225
Putrescine	Polyamine	-4.27094928	-4.24835776	-4.16225395	-4.25549149	2.1818E-07	2.1832E-07	2.1041E-07	2.0299E-07	4.6979E-05	4.6979E-05	0.00033017	4.3747E-05
Serotonin	Indole And Its Derivatives	-4.08890124	-3.67607239	-3.02019645	-2.17332745	0.01969912	0.02137845	0.02596244	0.03900307	0.09849111	0.08531585	0.07219232	0.08941662
Neopterin	Pteridines and derivatives	-3.48082292	-3.56946561	-3.72712733	-3.57962737	0.00013736	0.00013101	0.00012246	0.00013141	0.00422888	0.00352895	0.00219921	0.00168278
Indole-3-acetamide	Indole And Its Derivatives	-3.94544463	-4.48006986	-4.8249362	-4.98632791	0.004777	0.00426964	0.00404978	0.00396659	0.04358824	0.03172783	0.02270503	0.02011294
2-Picoline	Pyridine And Pyridine Derivatives	-4.34103671	-4.4063533	-3.9880455	-3.95488989	0.01288622	0.0127573	0.01372313	0.01381893	0.07888482	0.06705363	0.04769893	0.04584052
Sn-Glycero-3-Phosphocholine	Cholines	-4.43139705	-3.90612053	-3.06713628	-3.41890967	0.03858826	0.04133331	0.04084202	0.0452143	0.13305231	0.12371288	0.10001653	0.09823542
Allantoin	others	-5.26088907	-5.36381033	-5.19390846	-4.53725796	0.00019772	0.00019496	0.00019908	0.00022095	0.0047342	0.00420137	0.00272404	0.00244177
Dethiobiotin	Others	-2.09310064	-2.67871259	-2.02838744	-2.49109972	4.2278E-05	6.1391E-06	2.2188E-05	5.4774E-06	0.00182119	0.00052919	0.00073563	0.0002951
Triethylamine	Hydrocarbon derivative	-2.53705973	-2.34902806	-2.01939208	-1.99688631	0.00259984	0.00307956	0.00438436	0.00451277	0.03028461	0.0254098	0.02332911	0.02185397
Orotic Acid	CoOthersEnzyme Factor & vitamin	-2.09136889	-2.18933543	-2.27894077	-2.42635822	0.00589772	0.00532798	0.00487922	0.00427696	0.04861878	0.03892137	0.02564567	0.02101238
1,2-Dichloroethane	Hydrocarbon derivative	-5.25167899	-5.21395328	-5.30243024	-5.33580582	0.04357734	0.04367309	0.04345266	0.04337323	0.14337277	0.12632956	0.10454795	0.09636011

Table S6. KEGG enrichment analysis of DEMs shared by F vs H, S vs H and M vs H

#KEGG n	29	KEGG N	231			
#Pathway	ko ID	Unique co	compound	Uni all	compound all	
Metabolic pathways	ko01100	26	202	29	231	MEDN240:L-Gulonic-Γ-La C01040+C00169+C00507+C05570+C00355+C06752+C00243+C00429+C00149+C00392+C00166+C00491+C02693+C00295+C00231+C00075+C00979+C01127+C00257+C01019+C00213+C00049+C00134+C02067+C00780+C00
Cysteine and methionine metabolism	ko00270	3	18	29	231	MEDN616:O-Acetyl-L-seri C00979+C00049+C00491
ABC transporters	ko02010	5	43	29	231	MEDP127:Putrescine;MED C00134+C00243+C00049+C00392+C00491
Protein digestion and absorption	ko04974	3	26	29	231	MEDP127:Putrescine;MED C00134+C00049+C00491
Glycine, serine and threonine metab	ko00260	2	19	29	231	MEDN009:L-Aspartic Acid C00049+C00213
Arginine and proline metabolism	ko00330	2	18	29	231	MEDN404:Sarcosine;MEDI C00213+C00134
Arginine biosynthesis	ko00220	2	12	29	231	MEDN615:Carbamoyl pho: C00169+C00049
Alanine, aspartate and glutamate me	ko00250	2	11	29	231	MEDN009:L-Aspartic Acid C00049+C00169
Histidine metabolism	ko00340	2	8	29	231	MEDP437:Ergothioneine;N C05570+C00049
beta-Alanine metabolism	ko00410	2	9	29	231	MEDN009:L-Aspartic Acid C00049+C00429
Pantothenate and CoA biosynthesis	ko00770	2	10	29	231	MEDN009:L-Aspartic Acid C00049+C00429
Carbon metabolism	ko01200	6	18	29	231	MEDN009:L-Aspartic Acid C00049+C00149+C00231+C00979+C00257+C00169
2-Oxocarboxylic acid metabolism	ko01210	2	23	29	231	MEDN339:Phenylpyruvic / C00166+C00049
Biosynthesis of amino acids	ko01230	5	49	29	231	MEDN615:Carbamoyl pho: C00169+C00049+C00231+C00979+C00166
Neuroactive ligand-receptor interact	ko04080	3	13	29	231	MEDN009:L-Aspartic Acid C00049+C00075+C00780
Central carbon metabolism in cance	ko05230	2	25	29	231	MEDN009:L-Aspartic Acid C00049+C00149
Glyoxylate and dicarboxylate metab	ko00630	2	12	29	231	MEDN200:L-Malic Acid;M C00149+C01127
Taste transduction	ko04742	2	11	29	231	MEDP081:Serotonin;MED C00780+C00149
Pyrimidine metabolism	ko00240	5	21	29	231	MEDN244:Orotic Acid;ME C00295+C00169+C02067+C00075+C00429
Pentose phosphate pathway	ko00030	2	6	29	231	MEDP236:Gluconic Acid;N C00257+C00231
Ascorbate and aldarate metabolism	ko00053	2	6	29	231	MEDN240:L-Gulonic-Γ-La C01040+C00231
Fructose and mannose metabolism	ko00051	3	5	29	231	MEDN232:L-Rhamnose;M C00507+C01019+C00392
Tryptophan metabolism	ko00380	2	17	29	231	MEDP081:Serotonin;MED C00780+C02693

Table S7. KEGG enrichment analysis of DEMs unique to F vs H

#KEGG n	13	KEGG N	231			
#Pathway	ko ID	Unique con	compound	Uni all	compound all	
Metabolic	ko01100	13	202	13	231	MEDP036: C02237+C00144+C02376+C01829+C00468+C00262+C03740+C06153+C00362+C01367+C00417+C00097+C02465
Glutathione	ko00480	2	12	13	231	MEDP028: C03740+C00097
Purine meta	ko00230	4	16	13	231	MEDN163 C00262+C01367+C00362+C00144
Tyrosine m	ko00350	2	19	13	231	MEDN179 C01829+C02465
Neuroactive	ko04080	2	13	13	231	MEDN179 C01829+C02465
Thyroid hor	ko04918	2	6	13	231	MEDN179 C01829+C02465
Thyroid hor	ko04919	2	3	13	231	MEDN179 C01829+C02465
Bile secreti	ko04976	2	11	13	231	MEDP184: C02465+C01829
Autoimmur	ko05320	2	2	13	231	MEDN179 C01829+C02465

Table S8. Lipidomic data of F vs H

Compounds	Class	Log₂ FC				P value				FDR			
		F1/H	F2/H	F3/H	F4/H	F1/H-P	F2/H-P	F3/H-P	F4/H-P	F1/H-FDR	F2/H-FDR	F3/H-FDR	F4/H-FDR
3-Hydroxy-tetradecenoyl- carnit	Fatty Acyls	0.732891	1.058621	0.936478	1.322227	0.035259	0.006774	0.003624	0.003958	0.114833	0.078384	0.043978	0.038373
CE(18:0)	Steroids and steroid derivatives	-0.65621	-0.78053	-0.9131	-1.32363	0.017791	0.008787	0.003213	0.000636	0.085116	0.085183	0.043978	0.0148
Cer(d18:0/18:0)	Sphingolipids	1.837063	1.945024	1.959347	1.863655	0.000374	0.001599	0.011023	0.002918	0.012851	0.035426	0.074975	0.0343
DG(16:0/20:2/0:0)	Glycerolipids	3.156343	3.856241	3.285843	4.154154	0.02941	0.024028	0.01167	0.014896	0.026971	0.042183	0.030161	0.012065
DG(14:1/22:3/0:0)	Glycerolipids	1.757707	1.36161	1.832577	2.79635	0.001871	0.000903	0.001274	0.004844	0.043743	0.108438	0.043978	0.069247
DG(16:0/16:1/0:0)	Glycerolipids	1.881072	2.126148	1.704713	2.106992	0.005756	0.005341	0.005894	0.000544	0.049522	0.073197	0.053874	0.014093
DG(16:1/18:3/0:0)	Glycerolipids	1.941991	1.465783	1.300218	2.034405	0.00183	0.002259	0.001397	0.000398	0.142565	0.125179	0.197948	0.07012
DG(16:1/20:2/0:0)	Glycerolipids	1.072046	1.264273	1.538108	1.928656	0.034651	0.017008	0.014229	0.0011	0.114833	0.11711	0.084167	0.01919
DG(18:2/20:1/0:0)	Glycerolipids	0.607559	0.974156	0.852753	1.760549	0.165856	0.057757	0.087492	0.009319	0.265098	0.182381	0.201721	0.057566
DG(18:1/20:5/0:0)	Glycerolipids	0.5807	0.903268	1.303825	1.638523	0.168058	0.056314	0.039592	0.007025	0.266602	0.18114	0.143187	0.050553
DG(14:1/22:2/0:0)	Glycerolipids	0.932721	0.848304	1.141428	1.60097	0.071348	0.066491	0.022099	0.010441	0.161692	0.192576	0.110178	0.062994
DG(16:0/20:1/0:0)	Glycerolipids	0.315536	0.27446	0.584002	1.26688	0.325896	0.341448	0.185707	0.036971	0.392623	0.424325	0.295454	0.120123
DG(16:0/20:3/0:0)	Glycerolipids	-0.11785	0.567547	3.479046	1.129547	0.427346	0.170898	0.148393	0.045957	0.464622	0.296733	0.27014	0.133658
DG(18:1/20:0/0:0)	Glycerolipids	-0.0374	-0.09887	0.028185	1.027809	0.453178	0.371021	0.470814	0.041666	0.475494	0.439493	0.483276	0.126946
DG(18:2/20:4/0:0)	Glycerolipids	0.460721	0.585942	0.673665	1.017436	0.046836	0.035329	0.011214	0.029214	0.132893	0.143006	0.075262	0.107649
(±)12-HETE	Eicosanoid	4.253631	4.206264	3.131	4.833536	0.057189	0.020265	0.08366	0.013177	0.046413	0.135231	0.074975	0.155493
PGF2α	Eicosanoid	2.559641	1.964423	4.061743	4.120179	0.004584	0.014321	0.003287	0.012599	0.274034	0.271702	0.283387	0.203016
5-iso PGF2VI	Eicosanoid	0.441651	0.942004	1.046965	3.611075	0.000185	0.00407	0.00081	0.002911	0.341491	0.226624	0.191782	0.163774
FFA(18:3)	Fatty acids	0.725108	0.713111	1.025713	2.444395	0.000574	0.000413	0.000196	0.000122	0.221987	0.198316	0.123757	0.153594
FFA(22:4)	Fatty acids	1.052038	1.109519	0.899904	1.148244	0.000766	0.002296	0.000304	0.030227	0.016211	0.042183	0.11776	0.107649
FFA(22:2)	Fatty acids	0.677078	1.178435	0.971017	1.096585	0.051758	0.056992	0.024603	0.015305	0.136633	0.181646	0.114488	0.073169
FFA(22:0)	Fatty acids	-1.4544	-2.23349	-2.06996	-1.76132	0.02937	0.008699	0.010351	0.014545	0.112175	0.085183	0.073169	
Oleate	Fatty acids	0.062306	-0.39327	1.544085	-1.27721	0.468427	0.298216	0.179695	0.013633	0.481535	0.397425	0.290341	0.070392
Hexadecanedioic acid	Fatty acids	1.204368	1.825559	1.045968	1.241864	0.00445	0.022625	0.014219	0.00439	0.043743	0.129106	0.084167	0.040859
Farnesene	Fatty acids	-2.45454	-2.26485	-2.09316	-2.11914	0.021206	0.099354	0.040713	0.01101	0.093595	0.130692	0.119472	0.103014
LPA(18:1/0:0)	Glycerophospholipids	1.772428	2.03575	1.915876	1.460178	0.090353	0.063735	0.029694	0.022971	0.180189	0.19093	0.125801	0.09322
LPC(12:0/0:0)	Glycerophospholipids	1.988682	2.371117	1.801665	1.842264	0.000744	0.006314	5.63E-06	1.13E-05	0.016211	0.054888	0.000627	0.001443
LPC(O-20:1/0:0)	Glycerophospholipids	-1.13589	-1.03422	-1.02353	-1.00529	0.001511	0.001595	0.000814	0.0009	0.023444	0.035426	0.022724	0.017457
LPE(0:0/20:2)	Glycerophospholipids	3.445042	3.841904	3.703691	3.978356	0.006102	0.002296	0.004961	0.000115	0.008841	0.062912	0.03243	0.0343
LPE(0:0/16:1)	Glycerophospholipids	-0.07068	0.757932	1.073369	1.106595	0.367639	0.097695	0.012512	0.022061	0.419987	0.228065	0.081588	0.091327
LPE(0:0/24:6)	Glycerophospholipids	-0.66718	-0.76482	-1.42669	-1.45359	0.02307	0.064546	0.000168	0.000182	0.09819	0.192533	0.008401	0.007048
(±)12-HEPE [(±)-12-hydroxy-5Z	Oxidized lipid	3.282307	2.116852	2.978332	3.340256	0.012684	0.00107	0.012782	0.008109	0.112175	0.143055	0.181135	0.130979
(±)12-HETE [(±)12-hydroxy-5Z	Oxidized lipid	4.427983	2.696736	2.907706	2.973186	0.000387	0.035031	0.004601	0.01084	0.171824	0.179255	0.225155	0.125467
(±)5-HETE [(±)5-hydroxy-6E,8	Oxidized lipid	1.822193	1.731564	2.142326	1.354389	0.053806	0.053525	0.092794	0.03204	0.138395	0.134432	0.207302	0.110711
PC(18:2/20:4)	Glycerophospholipids	-0.78523	-0.74641	-0.95072	-1.00767	0.000684	0.027987	0.00076	5.01E-06	0.016211	0.135231	0.022724	0.001443
PC(20:2/22:6)	Glycerophospholipids	-0.34713	-0.60314	-0.78538	-1.31232	0.109504	0.015342	0.035223	0.000113	0.207701	0.110402	0.139395	0.005671
PC(18:3/14:1)	Glycerophospholipids	-1.00139	-0.50561	-1.45072	-1.34596	0.005548	0.084355	0.000103	0.000236	0.049522	0.212563	0.00599	0.008666
PC(18:0/20:1)	Glycerophospholipids	-0.4436	-1.12383	-1.36652	-1.51313	0.22801	0.058529	0.039548	0.032651	0.318005	0.182381	0.143187	0.112139
PC(18:0/20:3)	Glycerophospholipids	-2.57687	-1.18011	-1.71535	-1.57176	6.98E-05	0.00714	0.000415	0.000609	0.006092	0.078384	0.015228	0.014662
PC(O-18:2/18:1)	Glycerophospholipids	-0.9777	-0.95595	-0.96387	-1.13392	0.00296	0.006123	0.003426	0.00221	0.033323	0.076855	0.043978	0.029102
PC(O-20:2/22:1)	Glycerophospholipids	-1.47469	-2.09499	-2.08116	-2.99846	0.058423	0.049075	0.035413	0.037923	0.326708	0.321543	0.309631	0.254751
PE(18:1/16:1)	Glycerophospholipids	0.85907	0.896259	1.022551	1.713802	0.029884	0.022072	0.009866	0.001353	0.112654	0.129106	0.072492	0.022486
PE(16:0/20:3)	Glycerophospholipids	0.345407	0.691279	1.102432	1.447521	0.125932	0.030966	0.01512	0.007657	0.223097	0.140033	0.086508	0.051893
PE(18:3/16:0)	Glycerophospholipids	0.481505	1.048007	1.280195	1.403102	0.05584	0.028092	0.00054	0.001459	0.141219	0.135231	0.018857	0.023678
PE(20:2/16:0)	Glycerophospholipids	0.886649	1.029766	0.646767	1.328299	0.00926	0.039356	0.05387	0.025245	0.065953	0.148714	0.162111	0.09931
PE(18:1/18:1)	Glycerophospholipids	0.051414	0.595945	0.706182	1.274643	0.432166	0.130439	0.020859	0.002655	0.466953	0.256277	0.106275	0.033094
PE(16:1/16:0)	Glycerophospholipids	0.646717	1.001911	0.841791	1.254601	0.034365	0.014165	0.024995	0.020742	0.114833	0.108438	0.114662	0.089406
PE(18:1/18:2)	Glycerophospholipids	0.308513	0.834889	0.842207	1.216899	0.118317	0.134253	0.010444	0.002766	0.217254	0.260302	0.074384	0.033871
PE(18:1/16:0)	Glycerophospholipids	0.702429	0.973992	0.941321	1.174923	0.008155	0.005795	0.014999	0.001881	0.059916	0.074905	0.086508	0.027942
PE(18:2/16:0)	Glycerophospholipids	0.856151	1.135298	1.083812	1.155865	0.002932	0.034633	0.011029	0.002504	0.033323	0.142199	0.074975	0.03237
PE(18:1/20:4)	Glycerophospholipids	0.602911	0.785835	0.915018	1.144188	0.00199	0.031528	0.020497	0.005813	0.026971	0.140033	0.105465	0.046728
PE(22:6/20:1)	Glycerophospholipids	1.104173	1.071248	0.733964	1.13255	0.009958	0.00107	0.052794	0.005557	0.069508	0.034544	0.162111	0.046176
PE(18:2/14:0)	Glycerophospholipids	0.22172	0.855868	1.058296	1.1133	0.314543	0.116606	0.003648	0.003145	0.387215	0.241517	0.043978	0.0343
PE(14:0/22:6)	Glycerophospholipids	0.684661	1.148661	1.379301	1.071759	0.055355	0.05452	0.007193	0.00542	0.140888	0.179255	0.061226	0.045583
PE(18:1/18:0)	Glycerophospholipids	0.247405	0.584922	0.709438	1.052673	0.192325	0.12131	0.035351	0.014822	0.290858	0.247587	0.133959	0.073169
PE(16:1/18:0)	Glycerophospholipids	0.340382	0.808883	0.727173	1.021532	0.07113	0.010672	0.005481	0.002107	0.161692	0.095704	0.05365	0.028279
PE(20:4/22:2)	Glycerophospholipids	0.036104	-0.55366	-1.12848	-1.40203	0.461089	0.153713	0.001719	0.000171	0.476802	0.281606	0.031571	0.007048
PE(P-18:2/16:0)	Glycerophospholipids	-0.65967	-0.82465	-0.86965	-1.0651	0.048543	0.074287	0.005285	4.47E-05	0.135045	0.200655	0.05365	0.003119
PE(P-18:2/20:3)	Glycerophospholipids	-0.79807	-1.1557	-1.2334	-1.11779	0.001253	0.000122	3.73E-06	1.24E-05	0.020774	0.007128	0.000627	0.001443
PE(P-20:2/20:2)	Glycerophospholipids	-1.56728	-1.43213	-1.64054	-1.27486	7.03E-06	3.69E-05	5.37E-06	3.28E-05	0.001635	0.002859	0.000627	0.002546
PE(P-18:2/18:2)	Glycerophospholipids	-0.52204	-0.80443	-1.12382	-1.40226	0.052181	0.017829	0.000576	0.000172	0.136633	0.11711	0.019159	0.007048
PE(18:2/20:2)	Glycerophospholipids	-1.12596	-1.38181	-1.62322	-1.46111	0.000122	2E-05	6.23E-07	1.71E-06	0.008200	0.002327	0.000435	0.001194
PE(P-18:2/18:1)	Glycerophospholipids	-1.34364	-1.71902	-1.88436	-1.91779	0.00019	1.29E-05	6.29E-06	6.41E-06	0.008841	0.002251	0.000627	0.001443
PE(P-18:2/20:1)	Glycerophospholipids	-1.3963	-1.54926	-1.83692	-2.00009	0.080513	0.045312	0.107416	0.039186	0.015422	0.016427	0.008633	0.005671
PE(P-18:2/18:3)	Glycerophospholipids	-1.59694	-0.87394	-1.16568	-2.07055	0.034617	0.032079	0.072561	0.022068	0.093683	0.229632	0.144252	0.062994
PI(18:2/18:0)	Glycerophospholipids	1.24128	1.100703	0.976307	1.097714	0.010891	0.067275	0.053573	0.030691	0.071179	0.192596	0.162111	0.107649
PS(18:1/22:6)	Glycerophospholipids	1.929859	1.939216	1.816299	1.643889	0.000168	0.001636	0.008221	0.00035	0.008841	0.035426	0.065341	0.011098
TG(14:0/22:1/22:3)	Glycerolipids	2.530847	3.163348	3.558783	4.170396	1.71E-05	1.86E-05	1.97E-05	1.88E-05	0.077097	0.029454	0.081588	0.054107
TG(18:2/18:3/20:4)	Glycerolipids	1.907355	2.187941	2.712237	2.674074	0.029254	0.036686	0.064876	0.044103	0.012851	0.142277	0.150105	0.062994
TG(18:3/18:3/18:3)	Glycerolipids	-1.35806	-0.1598	0.454331	2.591791	0.030745	0.008457	0.01362	0.009289	0.071179	0.465283	0.354009	0.240122
TG(18:1/18:1/20:0)	Glycerolipids	-0.67098	0.062852	0.606658	2.179717	0.013116	0.00902	0.007992	0.00748	0.312787	0.478637	0.273431	0.170494
TG(16:0/18:0/22:3)	Glycerolipids	1.474583	1.821977	1.586085	2.106836	0.123512	0.469439	0.002025	0.001996	0.049522	0.05436	0.051679	0.005671
TG(14:0/22:3/22:4)	Glycerolipids	1.224878	1.453811	1.261318	1.878186	0.015747	0.011317	0.003613	0.006113	0.08153	0.096324	0.043978	0.046728
TG(14:0/20:2/22:2)	Glycerolipids	0.828815	1.400443	1.212017	1.86619	0.014444	0.005438	0.008918	0.003713	0.080657	0.073197	0.069162	0.03668
TG(18:1/18:3/20:0)	Glycerolipids	0.217134	0.744181	0.861473	1.664225	0.261735	0.033303	0.024577	0.01095	0.342118	0.140033	0.114488	0.062994
TG(14:0/22:4/22:4)	Glycerolipids	2.284213	2.586025	1.604119	1.476575	0.002007	0.047008	0.012708	0.034105	0.026971	0.165822	0.081588	0.113902
TG(18:2/18:2/20:0)	Glycerolipids	0.136132	0.657789	0.66104	1.35712	0.323551	0.03156	0.034491	0.01094	0.392081	0.140033	0.148081	0.062994
TG(16:1/20:1/20:2)	Glycerolipids	-0.12746	0.431547	0.363936	1.317693	0.328337	0.083473	0.153521	0.030472	0.393778	0.212478	0.272666	0.107649
TG(14:0/20:1/22:2)	Glycerolipids	-0.01997	0.435417	0.498753	1.179537	0.473213	0.087141	0.078368	0.025326	0.485026	0.218767	0.193046	0.09931
TG(14:0/20:5/22:4)	Glycerolipids	0.862815	1.448211	1.096723	1.171199	0.01581	0.052076	0.005474	0.026708	0.08153	0.175163	0.05365	0.103566
TG(14:0/20:5/22:3)	Glycerolipids	0.958314	1.25658	1.289513	1.164696	0.007246	0.022542	0.003835	0.00589	0.056262	0.129106	0.045365	0.046728
TG(14:0/18:3/22:1)	Glycerolipids	0.143305	0.530674	0.574017	1.14321	0.296111	0.071882	0.065143	0.039756	0.370786	0.198316	0.181154	0.126712
TG(14:1/14:1/22:3)	Glycerolipids	0.411214	0.858473	0.458976	1.110463	0.058527	0.071401	0.062302	0.043672	0.144279	0.205626	0.177496	0.130827
TG(14:0/20:1/20:1)	Glycerolipids	0.509187	0.821977	0.776724	1.10684	0.051154	0.004146	0.01739	0.008423	0.136281	0.062912	0.094828	0.054972
TG(14:0/20:2/22:4)	Glycerolipids	-0.01118	0.553877	0.307815	1.106744	0.488277	0.149325	0.185823	0.013816	0.491985	0.277943	0.295454	0.070392
TG(18:1/18:3/20:1)	Glycerolipids	-0.50991	0.373252	0.070203	1.096099	0.102354	0.162646	0.426741	0.021715	0.199773	0.291966	0.46226	0.091307
TG(14:0/20:3/22:1)	Glycerolipids	0.084783	0.4021	1.001136	1.078581	0.421262	0.126518	0.068758	0.003347	0.460158	0.253132	0.185316	0.035401
TG(18:1/18:3/20:4)	Glycerolipids	0.852752	1.108224	1.292052	1.077181	0.017804	0.017154	0.005894	0.009172	0.085116	0.11711	0.053874	0.057566
TG(18:0/18:1/18:2)	Glycerolipids	0.384664	0.433441	0.528006	1.040391	0.083429	0.008009	0.04538	0.0036	0.173313	0.081021	0.15282	0.036542
TG(16:0/20:4/22:5)	Glycerolipids	1.020815	0.976493	1.772852	1.035576	0.00601	0.017401	0.021907	0.048099	0.049522	0.11711	0.110178	0.138381
TG(14:0/20:3/20:5)	Glycerolipids	0.554584	1.000365	0.992563	1.035273	0.115594	0.081054	0.038692	0.041673	0.214662	0.208686	0.142895	0.126946
TG(18:0/18:3/20:2)	Glycerolipids	-0.07914	0.430927	0.267478	1.001518	0.411076	0.128127	0.222412	0.014944	0.452573	0.254774	0.323424	0.073169
TG(14:0/20:0/20:0)	Glycerolipids	-2.94121	-4.26743	-3.90332	-3.53402	0.021052	0.023798	0.026928	0.026418	0.170367	0.189304	0.180125	0.160488

Table S9. Lipidomic data of S vs H and M vs H

Compounds	Class	Log₂ FC				P value				FDR			
		ST1/H	ST2/H	MT1/H	MT2/H	ST1/H-P	ST2/H-P	MT1/H-P	MT2/H-P	ST1/H-FDR	ST2/H-FDR	MT1/H-FDR	MT2/H-FDR
Glycocholic Acid	Bile Acids	-1.562566307	-1.734053726	-1.902328797	-2.278651031	0.02306349	0.015077963	0.0122502	0.008120827	0.15938927	0.15098673	0.04621967	0.02391703
Cer(d18:1/18:1)	Sphingolipids	3.103373474	2.694176315	2.087149306	2.386808302	0.035759384	0.000440324	0.000512193	0.012090853	0.12561027	0.21183703	0.01461782	0.09740866
Cer(d18:0/18:0)	Sphingolipids	1.806648121	2.023396674	2.062599441	2.280526728	0.016516581	0.015809763	0.017251447	0.00675199	0.13251234	0.15116732	0.05817155	0.02138939
DG(16:0/20:2/0:0)	Glycerolipids	3.419566256	4.760460977	3.790298648	4.230188035	0.012879856	0.022808216	0.010695387	0.014146693	0.05161576	0.15668322	0.00210474	0.00098919
DG(14:1/22:3/0:0)	Glycerolipids	1.946986599	2.52513302	2.184108717	2.562694047	0.011953867	0.040682557	0.001654452	0.055821581	0.12460037	0.15568394	0.00179685	0.0014716
DG(16:0/16:1/0:0)	Glycerolipids	1.343366759	2.446915514	2.235581794	2.947646712	0.025046109	0.040006045	0.001941206	0.000638302	0.16619923	0.21183703	0.01566089	0.00441933
DG(16:1/18:3/0:0)	Glycerolipids	1.615029147	1.258379545	1.712432931	1.621531685	0.001638189	0.017733488	3.79113E-05	4.53497E-05	0.23014562	0.19501475	0.03205295	0.0029447
DG(16:1/20:2/0:0)	Glycerolipids	1.158272128	2.067739658	1.716402514	1.976972407	0.045185513	0.020005295	0.001901897	0.001195212	0.209088	0.17434653	0.01566089	0.00641737
FFA(22:0)	Fatty acids	-1.680426826	-1.715484992	-1.526469728	-1.970871915	0.017237641	0.01695126	0.020915218	0.011453033	0.13518959	0.15568394	0.06605802	0.03028113
LPC(12:0/0:0)	Glycerophospholipids	1.592738534	1.677657267	1.879575129	2.131799559	0.000213342	0.000792147	2.63225E-07	1.0296E-07	0.01861409	0.02764593	9.7622E-05	4.6645E-05
(±)12-HEPE [(±)-12-hydro:	Oxidized lipid	1.203063199	1.994467481	2.472382374	3.143034687	0.01085773	0.022254719	0.000927184	0.004009076	0.12561027	0.13828206	0.00414862	0.00021677
PC(18:0/20:3)	Glycerophospholipids	-1.938769454	-1.093608196	-1.223701153	-0.811688441	0.000176746	0.003882864	0.002374377	0.020975714	0.01831602	0.0774354	0.017558	0.04707733
PC(O-20:2/22:1)	Glycerophospholipids	-1.244412763	-2.774862923	-2.579115731	-1.341969722	0.029745143	0.027803613	0.02724922	0.027952109	0.40841061	0.28920277	0.2649314	0.31493431
PE(18:2/20:4)	Glycerophospholipids	1.194094437	0.937574948	1.057427307	0.734281086	0.002428119	0.008602052	0.001564624	0.030090036	0.06277137	0.12050477	0.01461782	0.06070456
PE(P-18:0/18:0)	Glycerophospholipids	-1.330736065	-0.612572106	-1.173211316	-0.352033952	7.82174E-06	0.015574562	1.12867E-05	0.024522692	0.00295969	0.15098673	0.0015093	0.05220853
PI(18:2/18:0)	Glycerophospholipids	1.166854807	1.717360487	1.600095702	1.643987518	0.000275676	0.000773877	0.006566721	0.00147547	0.01879801	0.02764593	0.03205295	0.00740919
PS(18:1/22:6)	Glycerophospholipids	1.91441964	1.740121496	1.830156627	1.866477265	0.001905388	0.000790976	5.03158E-06	6.39596E-06	0.05330562	0.02764593	0.00087801	0.00027902
TG(14:0/22:1/22:3)	Glycerolipids	2.45514207	3.332584857	2.912408929	3.142038268	1.99341E-05	2.08032E-05	1.94126E-05	2.25595E-05	0.12561027	0.18275052	0.01155669	0.01472808
TG(18:2/18:3/20:4)	Glycerolipids	1.956422308	2.626290364	2.971456773	2.741472617	0.012330324	0.010373693	0.000184251	3.41608E-06	0.05008103	0.0869969	0.00210474	0.00021677
TG(14:0/22:3/22:4)	Glycerolipids	1.110069554	1.001875522	1.249508459	1.388617688	0.027841387	0.065652631	0.001623118	0.008041958	0.1705897	0.22161326	0.01461782	0.02384662
TG(14:0/20:2/22:2)	Glycerolipids	1.104910867	1.287741589	1.210856405	1.593205222	0.028105753	0.024176167	0.001506904	0.002423129	0.1705897	0.18543917	0.0146086	0.0105709
TG(14:0/20:0/20:0)	Glycerolipids	-3.784389555	-0.839636612	-2.122050268	-0.297337049	0.02549273	0.032673181	0.028730109	0.035735915	0.23014562	0.35172628	0.18322975	0.4216428

Table S10. KEGG enrichment analysis of DEIs shared by F vs H, S vs H and M vs H

#Pathway	ko ID	Unique con	compound	Uni all	compound all	
#KEGG	n 16	KEGG	N 524			
Metabolic	ko01100	14	418	16	524	LIPID-N-0 C01194+C00641+C02737+C00157+C00422+C00195+C00641+C00422+C00422+C00422+C00641+C00641+C00641+C00422
Adipocytol	ko04920	2	46	16	524	LIPID-N-0 C00162+C00195
Insulin resi	ko04931	7	237	16	524	LIPID-P-1 C00422+C00422+C00422+C00195+C00422+C00422+C00162
Leishmania	ko05140	2	17	16	524	LIPID-P-0 C00195+C02737
Glycerolipi	ko00561	11	287	16	524	LIPID-P-0 C00641+C00641+C00422+C00641+C00641+C00422+C00422+C00422+C00422+C00162+C00641
Inositol ph	ko00562	6	56	16	524	LIPID-P-0 C00641+C00641+C00641+C00641+C01194+C00641
Glycerophc	ko00564	9	217	16	524	LIPID-P-0 C00641+C01194+C00641+C00641+C02737+C00641+C00157+C04230
Phosphatid	ko04070	6	59	16	524	LIPID-P-0 C00641+C00641+C00641+C01194+C00641+C00641
Long-term	ko04730	5	55	16	524	LIPID-P-0 C00641+C00641+C00641+C00641+C00641
Thermogen	ko04714	6	227	16	524	LIPID-P-1 C00422+C00162+C00422+C00422+C00422+C00422
Regulation	ko04923	6	227	16	524	LIPID-P-1 C00422+C00422+C00422+C00162+C00422+C00422
Fat digestic	ko04975	6	234	16	524	LIPID-P-0 C00422+C00422+C00422+C00162+C00422+C00422
Vitamin dig	ko04977	6	231	16	524	LIPID-P-1 C00422+C00422+C00162+C00422+C00422+C00422
Cholesterol	ko04979	6	229	16	524	LIPID-P-0 C00422+C00422+C00422+C00422+C00422+C00162
Choline me	ko05231	3	123	16	524	LIPID-P-0 C04230+C00157+C00162

Table S11. KEGG enrichment analysis of DEEs unique to F vs H

#KEGG i 58 KEGG N 524

#Pathway	ko ID	Unique co	common	Uni all	compound all
Glycerolip	ko00561	32	287	58	524	LIPID-P-t C00422<C00422<C00422<C00641<C00422<C00681<C00422<C00422<C00422<C00641<C00162<C00162<C00422<C00641<C00422<C00422<C00641<C00422<C00422<C00641<C00422<C00162<C00162<C00422<C00422<C00422<C00641<C00422
Inositol pl	ko00562	7	56	58	524	LIPID-P-t C00641<C00641<C00641<C00641<C00641<C00641
Glycerolip	ko00564	31	217	58	524	LIPID-P-t C00350<C00438<C00350<C00641<C00641<C00641<C00350<C00641<C00350<C00157<C00350<C00350<C00438<C00350<C00350<C00350<C00641<C00350<C00641<C00350<C00350<C00641<C00157<C00438<C00157<C00350<C00641
Metabolic	ko00100	51	418	58	524	LIPID-P-t C00350<C00422<C00422<C00422<C00422<C00641<C00641<C00422<C00639<C00350<C19615<C00350<C00350<C00422<C00422<C00422<C00157<C00641<C00422<C00157<C00350<C00350<C00350<C00641<C00350<C00422<C00350<C00041<C00422<C00641<C00350<C00422<C00350<C00157<C00422<C00422<C00350<C00350<C00681<C00422<C00422<C00422<C00157<C00422<C00422<C00157<C
Phosphati	ko04070	7	59	58	524	LIPID-P-t C00641<C00641<C00641<C00641<C00641<C00641
Lono-tato	ko04730	7	55	58	524	LIPID-P-t C00641<C00641<C00641<C00641<C00641<C00641
Arachidon	ko00590	5	59	58	524	LIPID-N- C00639<C00157<C00157<C00157<C00157
Phospholi	ko04072	2	7	58	524	LIPID-P-t C00681<C00639
Neurotrust	ko04080	2	5	58	524	LIPID-P-t C00681<C00639
Fatty acid	ko00062	3	34	58	524	LIPID-N- C00162<C00162<C00162
Fatty acid	ko00071	3	35	58	524	LIPID-N- C00162<C00162<C00162
AMPK sig	ko04152	3	33	58	524	LIPID-N- C00162<C00162<C00162
Thermoex	ko04714	24	227	58	524	LIPID-P- C00422<C00422<C00422<C00422<C00422<C00422<C00162<C00422<C00422<C00422<C00422<C00422<C00422<C00162<C00422<C00422<C00422<C00422<C00162
Insulin sec	ko04911	3	33	58	524	LIPID-N- C00162<C00162<C00162
Adipocyte	ko04920	3	46	58	524	LIPID-N- C00162<C00162<C00162
Regulation	ko04920	24	227	58	524	LIPID-N- C00162<C00162<C00162<C00422<C00422<C00422<C00422<C00162<C00422<C00422<C00162<C00422<C00422<C00162<C00422<C00422<C00422<C00422<C00422<C00422<C00162<C00422<C00422<C00422<C00422
Type II di	ko04930	3	33	58	524	LIPID-N- C00162<C00162<C00162
Insulin res	ko04931	24	237	58	524	LIPID-P- C00422<C00422<C00422<C00422<C00422<C00162<C00422<C00422<C00162<C00422<C00422<C00422<C00162<C00422<C00422<C00162<C00422<C00422<C00162<C00422<C00422<C00162<C00162
Non-alcoh	ko04932	3	33	58	524	LIPID-N- C00162<C00162<C00162
Fat digest	ko04975	25	234	58	524	LIPID-P- C00422<C00422<C00422<C00422<C00422<C00422<C00162<C00422<C00422<C00162<C00422<C00422<C00422<C00681<C00422<C00162<C00422<C00162<C00422<C00422<C00162<C00422<C00422<C00422
Vitamin di	ko04977	25	231	58	524	LIPID-P- C00422<C00422<C00422<C00422<C00422<C00162<C00422<C00422<C00162<C00422<C00422<C00422<C00681<C00422<C00162<C00422<C00162<C00422<C00422<C00422<C00422<C00422<C00422
Cholester	ko04979	24	229	58	524	LIPID-P-t C00422<C00422<C00422<C00422<C00422<C00162<C00422<C00162<C00422<C00422<C00422<C00422<C00162<C00422<C00422<C00162<C00422<C00422<C00422<C00422
Choline tr	ko05231	7	123	58	524	LIPID-N- C00162<C00157<C00162<C00162<C00157<C00157<C00157
Linoleic a	ko00591	4	63	58	524	LIPID-P-t C00157<C00157<C00157<C00157
alpha-Lino	ko00592	4	57	58	524	LIPID-P-t C00157<C00157<C00157<C00157
Retrograd	ko04723	20	99	58	524	LIPID-N- C00350<C00350<C00157<C00157<C00350<C00350<C00350<C00350<C00157<C00350<C00157<C00350<C00350<C00350<C00350<C00350<C00350
Glycerolip	ko00565	16	46	58	524	LIPID-N- C00350<C00350<C00350<C00350<C00350<C00350<C00350<C00350<C00350<C00350<C00350<C00350<C00350<C00350<C00350<C00350
Autophae	ko04136	16	46	58	524	LIPID-N- C00350<C00350<C00350<C00350<C00350<C00350<C00350<C00350<C00350<C00350<C00350<C00350<C00350<C00350<C00350<C00350
Autophag	ko04140	16	44	58	524	LIPID-P- C00350<C00350<C00350<C00350<C00350<C00350<C00350<C00350<C00350<C00350<C00350<C00350<C00350<C00350<C00350<C00350
Pathogeni	ko05130	16	44	58	524	LIPID-N- C00350<C00350<C00350<C00350<C00350<C00350<C00350<C00350<C00350<C00350<C00350<C00350<C00350<C00350<C00350<C00350
Kaposi sa	ko05167	16	44	58	524	LIPID-P-t C00350<C00350<C00350<C00350<C00350<C00350<C00350<C00350<C00350<C00350<C00350<C00350<C00350<C00350<C00350<C00350

Table S12. Normalized expression levels of potential biomarkers

Table S13. Clinical characteristics of COVID-19 patients in this study

Characteristic	Fatal (n=9)				Severe (n=11)		Mild (n=14)	
	F1	F2	F3	F4	S1	S2	M1	M2
ALT (normal range 9-50 U/L)	46(22-66)	31(22-49)	39(27-59)	40(29-109)	39(24-56.5)	47(32.5-78.5)	29(13.8-37.5)	33(25.5-65)
AST (normal range 15-40 U/L)	38(34-74)	44(25-53)	32(27-42)	56(41-228)	29(24-43)	33(21.5-36.5)	26.5(20.3-30.3)	22.5(14.3-27.8)
Total bilirubin (normal range 0-21 μmol/L)	15(12-21.2)	25.6(12.2-35.1)	17.5(16.1-23.5)	18.3(16.2-19.7)	10.5(10-13.6)	10.1(7.55-13.1)	13.3(11-16.8)	9.3(7.4-11.4)
Patients with pre-existing liver conditions	1 (11.1%)				0 (0%)		2 (14.3%)	

Data are median (IQR)